[
  {
    "section": "epilepsy",
    "sectionName": "Epilepsy",
    "heading": "Maintenance Antiseizure Medications",
    "id": "maintenance-antiseizure-medications",
    "text": "Antiseizure medication SIDE-EFFECTS (always relay black boxed warnings) MedicationFDA approvedIdiosyncraticDose relatedAge Specific/otherBrivaracetam/Briviact2016Psychiatric, ataxia, dizziness, Drowsiness, fatigue Cannabidiol (Epidiolex)2018Anemia, infection tzars as zzz Greta  Fed zdSedation, diarrheal Carbamazepine/ Tegretol/XR 1968Dermatologic (SJS) rare hematologic, hepatic, SIADH, fluid retentionVertigo, visual disturbance (diplopia), lethargy, leukopeniaLow Na in adults; myoclonus in pts with general S/W, osteopeniaClobazam/Onfi2011Urticarial type reaction, SJS, rare. Sedation, ataxia, i"
  },
  {
    "section": "epilepsy",
    "sectionName": "Epilepsy",
    "heading": "Antiseizure drug indications",
    "id": "antiseizure-drug-indications",
    "text": "CONTINUUM: Lifelong Learning in Neurology. 22(1, Epilepsy):132-156, February 2016.    To"
  },
  {
    "section": "epilepsy",
    "sectionName": "Epilepsy",
    "heading": "Status Epilepticus Pathway",
    "id": "status-epilepticus-pathway",
    "text": "A definition and classification of status epilepticus – Report of the ILAE Task Force on Classification of Status Epilepticus” 2015:"
  },
  {
    "section": "epilepsy",
    "sectionName": "Epilepsy",
    "heading": "First-Line Agents",
    "id": "first-line-agents",
    "text": "·       Benzodiazepines are most effective when administered within the first 5-10 minutes of seizure activity, before GABA receptors have internalized.  Choose ONE of the following options:·       Lorazepam IV: 0.1 mg/kg (max 4 mg) administered over 2 minutes.  A second dose can be administered if the seizure persists beyond 3-5 mins after the first dose.·       Diazepam IV: 0.15-0.2 mg/kg (max 10 mg) administered over 2 minutes.  A second dose can be administered if the seizure persists beyond 3-5 mins after the first dose.·       If IV access is not available, choose ONE of the following op"
  },
  {
    "section": "epilepsy",
    "sectionName": "Epilepsy",
    "heading": "Second-Line Agents",
    "id": "second-line-agents",
    "text": "Under most circumstances, choose ONE of the following second-line agents.  If seizures persist 10-20 minutes after the second-line agent (+/- optimization) finishes infusing, strongly consider advancing to a continuous infusion agent (third-line agent) to improve the likelihood of quickly achieving seizure-control.     Fosphenytoin IV load: 20 mg PE/kg (max 1500 mg PE/dose), infused over 15 minutes If seizure persists 10 minutes after initial dose is complete, then can consider additional 10 mg/kg load (over 10 minutes) or, if unable to administer second bolus, escalate to third line agent Che"
  },
  {
    "section": "epilepsy",
    "sectionName": "Epilepsy",
    "heading": "Third-Line Agents",
    "id": "third-line-agents",
    "text": "The following medications administered as continuous infusion should be strongly considered if seizures persist 10-20 minutes after the second-line agent has finished infusing.  Refractory status epilepticus will typically not respond to alternative second-line agents.  Titrate to cessation of electrographic seizures or burst suppression.  In most cases, 24 hours of seizure control is recommended prior to slow withdrawal of continuous infusion. Hypotension is common and should be prepared for. Midazolam infusion: Give a 0.1-0.15 mg/kg IV bolus (over 2 minutes) and then begin continuous infusio"
  },
  {
    "section": "epilepsy",
    "sectionName": "Epilepsy",
    "heading": "General suggestions on how to wean continuous infusions",
    "id": "general-suggestions-on-how-to-wean-continuous-infusions",
    "text": "There are no data on the appropriate timing or rate of tapering continuous infusions in the treatment of refractory or super-refractory status epilepticus.  Generally speaking, coordinate with attending and primary team, weaning is typically 24-48 hours after cessation of seizures.   ·       Midazolam – decrease 0.1 mg/kg/hour every 1-3 hours ·       Ketamine – decrease 1 mg/kg/hour every 1-3 hours ·       Pentobarbital – decrease 1 mg/kg/hour every 1-3 hours ·       Propofol – decrease by 50% for 1-3 hours then discontinue"
  },
  {
    "section": "epilepsy",
    "sectionName": "Epilepsy",
    "heading": "General suggestions on how to wean continuous infusions",
    "id": "general-suggestions-on-how-to-wean-continuous-infusions-2",
    "text": "There are no data on the appropriate timing or rate of tapering continuous infusions in the treatment of refractory or super-refractory status epilepticus.  Generally speaking, coordinate with attending and primary team, weaning is typically 24-48 hours after cessation of seizures.   Midazolam – decrease 0.1 mg/kg/hour every 1-3 hoursPentobarbital – decrease 1 mg/kg/hour every 1-3 hoursKetamine – decrease 1 mg/kg/hour every 1-3 hoursPropofol – decrease by 50% for 1-3 hours then discontinue   Adjunctive Therapies Can be utilized in parallel with above treatments and in preparation for withdrawa"
  },
  {
    "section": "epilepsy",
    "sectionName": "Epilepsy",
    "heading": "Electroencephalogram (EEG)",
    "id": "electroencephalogram-eeg",
    "text": "An EEG should be ordered STAT after failure of the second-line agent to assess for subclinical seizure activity and to assist in medication titration.Titrate to cessation of electrographic seizures or burst suppression, which will be determined by discussion between neurology and critical care teams.  In most cases, if a continuous infusion was required, 24 hours of seizure control is recommended prior to slow withdrawal of continuous infusion.Reassess every two hours for oversuppression (<1 burst per page on EEG). If oversuppressed, decrease the infusion rate by 10-20%."
  },
  {
    "section": "epilepsy",
    "sectionName": "Epilepsy",
    "heading": "Supportive Care Goals",
    "id": "supportive-care-goals",
    "text": "Intubation and mechanical ventilation if GCS 3-8 Target normocapnea (PaCO2 40-45) Target normal BP for age. Avoid hypotension.  Assure good intravascular volume.  Be prepared for hypotension with continuous infusion agents and order vasopressor(s) to bedside). Avoid treatment of hyPERtension until seizures have stopped.Maintain normal systemic and cerebral perfusionCerebral autoregulation is frequently impaired during prolonged (>20-30 min) SEHOB at 30° Target normothermia (36.0°C-37.5°C) Consider scheduled antipyretics If using a cooling blanket, control shivering per TTM order set recommenda"
  },
  {
    "section": "epilepsy",
    "sectionName": "Epilepsy",
    "heading": "Diagnostic work-up/management of underlying causes of status epilepticus",
    "id": "diagnostic-work-up-management-of-underlying-causes-of-status",
    "text": "Most common causes of status epilepticus: In patients with known seizures or epilepsy:  breakthrough seizure, missed medication, and illness.  Thus, patients with known seizures may not require extensive work-up; however, work-up should always be tailored to the individual patient.  In patients with new onset status epilepticus: hypoglycemia, electrolyte disturbances, drug/toxin ingestion, intracranial pathology (such as intracranial hemorrhage, stroke, or tumor), CNS infection, and undiagnosed epilepsy.     Screen for fever, illness, dehydration, exposure, ingestion, or trauma. If signs or sy"
  },
  {
    "section": "epilepsy",
    "sectionName": "Epilepsy",
    "heading": "Neonatal Seizures",
    "id": "neonatal-seizures",
    "text": "Neonates typically do not have generalized seizures because their myelination is immature (ie, they are more likely to have focal seizures).Apneic spells may or may not be seizure.    Neonatal seizure etiologies (Rough timing guidelines—any of these can present at any time) < 24 hours24-72 hours72hr-1 weekHIEInfarctionMetabolicMeningitis/sepsisVenous clotHSVBlood: SDH, SAH, IVHIVHHypocalcemiaTORCHMeningitis/sepsisBenign neonatal convulsionPyridoxine dependenceStructural abnormality Drugs/withdrawal     Ischemia/hypercoaguabilityToxicHypoxic-ischemic EncephalopathyFocal ischemic strokeSinus Ven"
  },
  {
    "section": "epilepsy",
    "sectionName": "Epilepsy",
    "heading": "Neonatal Seizure Algorithm",
    "id": "neonatal-seizure-algorithm",
    "text": "Phenobarbital and fosphenytoin levels (guidelines, always refer to attending):  Neonates: Fosphenytoin level (ref 10-20 ug/ml): -       If less than < 10, give 15-20 PE/kg load -       If 10-16, give 10 PE/kg load -       If > 16, give another agent   Phenobarbital level (ref 15 - 40 mcg/ml): -       If < 20, give 20 mg/kg load -       If 20-35, give 10 mg/kg load -       If >35, give another agent"
  },
  {
    "section": "epilepsy",
    "sectionName": "Epilepsy",
    "heading": "IV Pyridoxine (vitamin B6) challenge",
    "id": "iv-pyridoxine-vitamin-b6-challenge",
    "text": "Use 100mg pyridoxine IV to be pushed over 1-3 minutes. It can also be slowly infused in over 15-30 min as IV push may cause burningIf no clinical response, the dose should be repeated up to a maximum of 500 mg, although corresponding change on EEG may be delayed by several hoursHave patient on CR monitor, cEEG, and vitals q 5 minutesProvider should be at the bedside during the injection/push and 5-10 min after injection to watch for any SEs (risk of apnea, cardiorespiratory depression, profound sedation) and to look at EEG monitoring.Can alternatively begin supplementation with 30 mg/kg/day of"
  },
  {
    "section": "epilepsy",
    "sectionName": "Epilepsy",
    "heading": "Home Rescue for prolonged seizure:",
    "id": "home-rescue-for-prolonged-seizure",
    "text": "Rectal diazepam (Diastat)Intranasal midazolam, prefilled (Nayzilam)Intranasal diazepam, prefilled (Valtoco)   Weight in kgIntranasal midazolam 0.2-0.3 mg/kg Dose = volumeFor school/ seizure action plan3–5 kg1 mg = 0.2 mL total0.1 mL per nostrilDiastat: use Diastat dosing chart6-9 kg2 mg = 0.4 mL total0.2 mL per nostrilDiastat: use Diastat dosing chart10–15 kg3 mg = 0.6 mL total0.3 mL per nostrilDiastat: use Diastat dosing chart16-26 kg5 mg = 1 mL total0.5 mL per nostrilMay prescribe midazolam at 1mL total27–32 kg8 mg = 1.6 mL total0.8 mL per nostrilDiastat: use Diastat dosing chart>=33kg10 mg"
  },
  {
    "section": "epilepsy",
    "sectionName": "Epilepsy",
    "heading": "Bridging Sick Kids with Benzos",
    "id": "bridging-sick-kids-with-benzos",
    "text": "Bridging Sick Kids with Benzos* Clonazepam 0.01-0.03mg/kg/day divided BID x 3-5 days  Formulations: ·       ODT: 0.125 mg, 0.25 mg, 0.5 mg, 1 mg ·       Tabs:  0.25mg; 0.5mg; 1 mg tabs ·       Solution: 0.1 mg/mL   * This approach is less effective in patients taking clobazam.  In this case, you can also consider using extra dose of maintenance medication.   IF you need to convert benzodiazepines, 20mg clobazam = 0.5mg clonazepam.  Also see:  http://www.benzo.org.uk/bzequiv.htm"
  },
  {
    "section": "epilepsy",
    "sectionName": "Epilepsy",
    "heading": "EEG Reading Basics",
    "id": "eeg-reading-basics",
    "text": "Sleep StagesStage W: WakefulnessDrowsiness: Fluctuation in alpha rhythm, general fronto-central slowing, overall loss of voltageStage N1: Vertex waves, positive occipital sharp transients of sleep (POSTS)Stage N2: Spindles and K complexes (vertex waves can persist)Stage N3: Slow wave sleep.  Appearance of delta activity (spindles can persist)Stage R:  REM sleep. Low-voltage fast activity with no alpha, rapid lateral eye movements   Neonatal EEG Normal Waveforms"
  },
  {
    "section": "epilepsy",
    "sectionName": "Epilepsy",
    "heading": "Helpful Tips:",
    "id": "helpful-tips",
    "text": "General ·       For questions regarding EEGs while on call, first consult with the primary attending, then call epileptologist for further assistance if necessary. ·       In patients with complex EEGs, consider reviewing prior studies to look for likeness (especially helpful with LGS).  The EEG techs can pull old studies for review by request. ·       Arousal patterns in young children can be mistaken for seizure.  For sudden high amplitude, semi-rhythmic activity starting out of sleep, watch video to r/o arousal pattern.   Neonatal EEG ·       Neonatal EEG can usually be read easier when con"
  },
  {
    "section": "epilepsy",
    "sectionName": "Epilepsy",
    "heading": "Ketogenic Diet",
    "id": "ketogenic-diet",
    "text": "High fat (80-90%), adequate protein, limited carbs   Efficacy Neal 2008 random prospective trial 38% of pts had > 50% reduction in seizures, 7% sz free, compared to 6% controls and zero sz free.John Hopkins 1997: 7% seizure free, 20% with >90% reduction in seizures, 50% with >50% reduction in seizures after 1 yearFreitas 2007: 54 children. 57% >75% seizure control.Henderson: pts stopped diet b/c had < 50% seizure reduction, 16% diet restrictions and 13 % had SEsCochrane review 2016: rates of seizure freedom reached as high as 55% in 4:1 KD group after three months and reported rates of seizure"
  },
  {
    "section": "epilepsy",
    "sectionName": "Epilepsy",
    "heading": "Vagus Nerve Stimulator (VNS)",
    "id": "vagus-nerve-stimulator-vns",
    "text": "VNS is not a cure. The VNS is used to help control or lessen the severity of seizures.  VNS is discussed prior to implantation at the epilepsy surgery conference to determine eligibility.   Basics for parents ·       The generator is implanted under the skin of the chest and electrodes are wrapped about the left vagus nerve in the neck.  ·       A stimulus is sent to the vagus nerve at programmed intervals to attempt to prevent seizures and family can use a magnet to activate the device at higher settings to try to abort a seizure.  Newer devices (106 and Sentiva) monitor heart rate and will g"
  },
  {
    "section": "epilepsy",
    "sectionName": "Epilepsy",
    "heading": "Infantile Spasms",
    "id": "infantile-spasms",
    "text": "Infantile spasms (IS) is an epilepsy of early infancy, affecting 3-4.5/10,000 live births, with typical onset 1-15 months (peak 4-9 months), M>F.  Often associated with developmental issues. Patients can have flexor, extensor, mixed flexor-extensor, and/or asymmetric spasms.  IS can mimic reflux or myoclonus.  Patients are often admitted for continuous EEG to definitively evaluate for infantile spasms.        Etiology Unknown etiology (30%).     Known etiology (70%) - Over 200 causes, such as: Some conditions more likely to predispose to IS (alphabetically)Aicardi syndrome, Abusive head trauma"
  },
  {
    "section": "epilepsy",
    "sectionName": "Epilepsy",
    "heading": "Treatment choices:",
    "id": "treatment-choices",
    "text": "(See Infantile Spasms Clinical Pathway for full details)  ProsConsACTH    (AdrenocorticotropinHormone; Corticotropin; Acthar gel)Likely most effectiveAdverse effects: Immune suppressant, edema, gastric bleeding, weight gain, irritability, sleep disturbance, HTN, cortical atrophy, HPA axis suppression, death Intramuscular injection. Most expensive – only available from specialty pharmacy.PrednisoloneLeast expensiveOral administrationAdverse effects: Immune suppressant, edema, gastric bleeding, weight gain, irritability, sleep disturbance, HTN, cortical atrophy, HPA axis suppression, death."
  },
  {
    "section": "epilepsy",
    "sectionName": "Epilepsy",
    "heading": "Follow-up for all therapies",
    "id": "follow-up-for-all-therapies",
    "text": "Following the initiation of any first-line treatment, efficacy of therapy should be assessed by 2 weeks. Short-term outcomes include cessation of spasms and EEG confirmation of resolution of hypsarrhythmia.  ·       EEG should be used to assess for resolution of spasms and hypsarrhythmia at 12-16 days.  ·       Clinic visit with pediatric neurology should occur at the same time frame as repeat EEG. ·       If spasms or hypsarrhythmia persist at 2 weeks, consider switching treatment to an alternative first-line treatment with a different mechanism of action. Follow the weaning protocols outline"
  },
  {
    "section": "epilepsy",
    "sectionName": "Epilepsy",
    "heading": "Febrile Seizures",
    "id": "febrile-seizures",
    "text": "Definition:  Seizure accompanied by fever (temperature ≥ 100.4°F or 38°C by any method withing surrounding 24hr period), without intracranial / central nervous system infection, that occurs in infants and children 6 - 60 months of age.  Epidemiology:  2-5% of children, 90% within first 3 years Simple febrile seizure: Brief <15 minutes and generalized Complex febrile seizure: Duration >15 minutes OR more than 1 seizure in 24 hours OR focal features; 20-30% of cases NB: with re: multiple within 24 hours (evidence suggests outcomes are similar to simple febrile sz - 'simple febrile sz flurry')"
  },
  {
    "section": "epilepsy",
    "sectionName": "Epilepsy",
    "heading": "Treatments:",
    "id": "treatments",
    "text": "Simple febrile seizure:  Geared towards underlying illness, (common with Roseola, Shigella, Varicella) Aggressive antipyretic therapy has not been shown to decrease risk of febrile seizures, as seizure is related to rate of temperature change, and frequently occurs before fever is documented Some old efficacy data for ppx ASMs, but risks generally > benefits (Ped. ’99; 103:1307). For complex febrile seizures marked by clusters, consider rescue medication Does not generally need EEG or imagingStill consider LP if c/f meningitis (NB: meningeal signs are difficult to observe in infants/toddlers)"
  },
  {
    "section": "epilepsy",
    "sectionName": "Epilepsy",
    "heading": "PROGNOSIS",
    "id": "prognosis",
    "text": "Prognosis after Simple: • Increased risk of recurrent febrile seizures ~30-33% will have one or more recurrences ~10% with 3 or more recurrencesMost (75%) recurrent febrile seizures occur within 1 year • No evidence of increased mortality, hemiplegia, or mental retardation.• Risk of epilepsy shown to be only slightly higher than that of the general population (1 --> 1.7%)      Risk Factors for First Febrile Seizure: Family history of febrile seizuresNeonatal discharge ≥ 28 daysDelayed developmentVery high feverChild care attendanceLow serum sodium   Risk Factors for Recurrence of Febrile Seizu"
  },
  {
    "section": "epilepsy",
    "sectionName": "Epilepsy",
    "heading": "First \"Unprovoked\" Afebrile Seizure",
    "id": "first-unprovoked-afebrile-seizure",
    "text": "Practice Parameter: evaluating a First Nonfebrile Seizure in Children. Neurology 2000;55:616-62   Diagnostics to rule out symptomatic etiologies in the ED: Electrolytes if the child is < 6 months old; otherwise not needed if the seizure has stopped and the child looks well, and has no known reason for electrolyte derangement.UTOX if prolonged post-ictal state or any suspicion (have a low threshold, strongly consider in adolescents)CBC and UA if infection suspected in an infant or child.LP: Strongly consider in all infants <6 months     Neuroimaging: Brain imaging is often not needed for genera"
  },
  {
    "section": "epilepsy",
    "sectionName": "Epilepsy",
    "heading": "Epilepsy diagnosis:",
    "id": "epilepsy-diagnosis",
    "text": "·      At least two unprovoked seizures occurring more than 24 hours apart. ·      One unprovoked seizure and a probability of further seizures that is similar to the general recurrence risk after two unprovoked seizures (ie  ≥ 60 %) ·      Diagnosis of an epilepsy syndrome. Considered resolved: If seizure-free for 10 years with no seizure medications for 5 years.   Epilepsydiagnosis.org: Information of seizures types / epilepsy syndromes / video examples"
  },
  {
    "section": "epilepsy",
    "sectionName": "Epilepsy",
    "heading": "Syndromes:",
    "id": "syndromes",
    "text": "Epilepsy with Myoclonic-Atonic Seizures (Formerly Myoclonic-Astatic Epilepsy or Doose Syndrome) See “Results of an international Delphi consensus in epilepsy with myoclonic atonic seizures/ Doose syndrome” by Joshi et al 2021 for diagnostic criteria ·       Age of onset: Usually 2-4 years but always within first 5 years of life ·       Development: normal prior to onset ·       Seizure types: Myoclonic, atonic/astatic, GTC, NCSE, tonic, absence. Must have myoclonic-atonic seizures. ·       EEG: Central theta ·       Treatment: Valproate, clobazam, and rufinamide are frequently used.  Very sens"
  },
  {
    "section": "epilepsy",
    "sectionName": "Epilepsy",
    "heading": "Epilepsy and Driving",
    "id": "epilepsy-and-driving",
    "text": "·      If child has genetic generalized epilepsy or history of absence seizures (ie JAE, JME), most would obtain 24 hour EMU study to evaluate for subtle clinical seizures ·      If noted to have discharges lasting 3 seconds or longer (or shorter with clinical correlate) most would not recommend driving ·      Consensus: should be 6 months seizure-free without changes to anti seizure medications prior to driving ·      Counseling recommendation: o   If you miss even a single dose of medication, no driving for 2-3 days o   If you don’t get a good night’s sleep, no driving for 1-2 days o   If an"
  },
  {
    "section": "epilepsy",
    "sectionName": "Epilepsy",
    "heading": "Seizure Semiology",
    "id": "seizure-semiology",
    "text": "Seizures  Seizures result from abnormal excessive rhythmic neurologic electrical activity. This abnormal activity can occur in both hemispheres (generalized seizure) or within one hemisphere (focal seizure), which may spread to the entire brain. Generalized tonic-clonic seizures – motions of which consist of a tonic phase with muscle stiffening, followed by a clonic phase with rhythmic muscle contractions. Focal seizures more often occur in the setting of cerebral insult. Unlike generalized seizures, symptoms of focal seizures vary according to the anatomic location of the abnormal electrical"
  },
  {
    "section": "epilepsy",
    "sectionName": "Epilepsy",
    "heading": "Electroclincal Syndromes (by Age)",
    "id": "electroclincal-syndromes-by-age",
    "text": "Electroclinical syndromes arranged by age at onset (revised ILAE Classifcation. Epilepsia, 51(4):676–685, 2010)    Neonatal period  Benign familial neonatal epilepsy (BFNE)  Early myoclonic encephalopathy (EME)  Ohtahara syndrome    Infancy Epilepsy of infancy with migrating focal seizures West syndrome Myoclonic epilepsy in infancy (MEI) Benign infantile epilepsy Benign familial infantile epilepsy Dravet syndrome Myoclonic encephalopathy in nonprogressive disorders    Childhood Febrile seizures plus (FS+) (can start in infancy) Panayiotopoulos syndrome Epilepsy with myoclonic atonic (previous"
  },
  {
    "section": "epilepsy",
    "sectionName": "Epilepsy",
    "heading": "Rite Review",
    "id": "rite-review",
    "text": "Hypothalamus: Anterior: cooling, circadian rhythm (suprachiasmatic nuc) --> * hyperthermia, insomnia Posterior: heat conservation --> * hypothermia, poikothermia Postero-lateral: arousal (histaminergic) --> *hypersomnia, narcolepsy Lateral: increases appetite --> *anorexia Medial: Decreases appetite --> *obesity     Hippocampus: Major input: alveolar pathway (from enorhinal cortex --> CA1, CA3 cells)Major Output: Perforant pathway (from subiculum --> dentate gyrus/granular cell layer), Mossy fibers (from dentate gyrus --> CA3 pyramidal cells ----> Fornix)Schaffer collaterals (crom CA3 pyramida"
  },
  {
    "section": "epilepsy",
    "sectionName": "Epilepsy",
    "heading": "EEG Tips",
    "id": "eeg-tips",
    "text": "Template:   Patient Name:    DOB: Conditions # of EEG channels: EKG channel: y/n # of Eye channels: LFF: HEF: Notch: Sensitivity: Timebase: State: awake/drowsy/sleep   Posterior Rhythm (Hz): Symmetry: Organization:   Activations: Hyperventilation: present/not present? symmetric/asymmetric? (was there \"build up\" or slowing and increase in amplitude with high quality HV?) Photic stimulation: (at what frequencies did the posterior rhythm appear to track with the photic stim rate? Was there photic response after 20 hz?)   Sleep: present/not present? Architecture normal/not normal? N1 slow rolling"
  },
  {
    "section": "epilepsy",
    "sectionName": "Epilepsy",
    "heading": "Alpha waves",
    "id": "alpha-waves",
    "text": "Alpha activity disappears normally with attention (eg, mental arithmetic, opening eyes). In most instances, it is regarded as a normal waveform.An abnormal exception is alpha coma, most often caused by hypoxic-ischemic encephalopathy of destructive processes in the pons (eg, intracerebral hemorrhage). In alpha coma, alpha waves are distributed uniformly both anteriorly and posteriorly in patients who are unresponsive to stimuli."
  },
  {
    "section": "epilepsy",
    "sectionName": "Epilepsy",
    "heading": "Beta waves",
    "id": "beta-waves",
    "text": "They tend to be small in amplitude and usually are symmetric and more evident anteriorly.Barbituates, benzodiazepines, bad brain"
  },
  {
    "section": "epilepsy",
    "sectionName": "Epilepsy",
    "heading": "Theta waves",
    "id": "theta-waves",
    "text": "Theta waves normally are seen in sleep at any age. In awake adults, these waves are abnormal if they occur in excess.Theta and delta waves are known collectively as slow waves."
  },
  {
    "section": "epilepsy",
    "sectionName": "Epilepsy",
    "heading": "Delta waves",
    "id": "delta-waves",
    "text": "These slow waves have a frequency of 3 Hz or less.They normally are seen in deep sleep in adults as well as in infants and children.Delta waves are abnormal in the awake adult.Often, they have the largest amplitude of all waves.Delta waves can be focal (local pathology) or diffuse (generalized dysfunction)."
  },
  {
    "section": "infectious-disease",
    "sectionName": "Infectious Disease",
    "heading": "CSF Profiles and MEP",
    "id": "csf-profiles-and-mep",
    "text": "Normal by Age:  WBCProteinGlucoseOP (cmH2O)Neonates    Preterm0-25 115 (65-150)50 (24-63) mg/dL55-105 % serum Term0-2290 (20-170)52 (34-119) mg/dL44-128 % serum0-8Children0-55-30 50-75 (2/3 serum)0-8 (<2 yrs)1-25 (>=2 yrs)Adults0-520-4045-90 (2/3 serum)6-25   CSF Profile in Certain Infections:  WBCDiffProteinGlucoseOPOtherBacterial100-5000PMNs50-100 (nl to high)lowHighPartially treated – cells usu high <48 hours after tx, PMNs initially, may change to monos, glucose may normalizeViral10-100Lymphs (can be PMNs in the first 24-48 hrs)40-80 (nl to high)nlNl-midly high Fungal20-500PMNs earl, then"
  },
  {
    "section": "infectious-disease",
    "sectionName": "Infectious Disease",
    "heading": "Bacterial Meningitis",
    "id": "bacterial-meningitis",
    "text": "Clinical presentation: FeversSeizures (this can be the only initial symptom at presentation in neonates and infants <12 month – AAP says to strongly consider LP for even simple febrile seizure if poorly vaccinated and 6-12 mo)Meningismus (nuchal rigidity, photophobia, headache, can test Brudzinski’s – involuntary lifting of legs with neck flexion, Kernig’s – hip and thigh flexed at 90 degrees results in painful extension at the knee) – only 5-30% sensitive, but 95-100% specific. Unreliable/less sensitive in infants.Etiology by age: NeonateGBS, enteric GNegs (e.coli), listeria, 1 mo to 23 moN."
  },
  {
    "section": "infectious-disease",
    "sectionName": "Infectious Disease",
    "heading": "Viral Meningitis",
    "id": "viral-meningitis",
    "text": "Clinical Presentation: same as bacterial above though course can be more indolent Evaluation: LP (see profiles below)Viral testing:MEP (Meningitis Encephalitis Panel: PCR for e.coli, h.flu, listeria, n.meningitidis, GBS, S.pneumo, CMV, EV, HSV 1&2, HHV6, parechovirus, VZV, Cryptococcus)Etiology by season:Most common cause of viral meningitis – EV (>80% in children), late summer early fall predominanceApproximately 5% HSV (II>I for meningitis – opposite in encephalitis)Failure to identify a specific pathogen is not uncommon   SeasonMeningitisEncephalitisOtherSummer/FallEVParechoEVParechoWest Ni"
  },
  {
    "section": "infectious-disease",
    "sectionName": "Infectious Disease",
    "heading": "Acute Flaccid Myelitis",
    "id": "acute-flaccid-myelitis",
    "text": "Symptoms: >90% with preceding mild URI or febrile viral illness. Acute onset flaccid paralysis of one or more extremities or cranial neuropathies (facial palsy, bulbar weakness, diplopia); can be asymmetric DDx: Includes EV-68, EV-71, WNV, polio, MOGAD, NMO, spinal cord stroke MRI: In enteroviral infections - Dorsal brainstem and longitudinally extensive spinal grey matter hyperintensity, usually non-enhancing, +/- nerve root enhancement LP: Pleocytosis common Tx: None proven to be effective. IVIG is used most widely. Steroids worsened outcome in some animal models but could be considered if l"
  },
  {
    "section": "infectious-disease",
    "sectionName": "Infectious Disease",
    "heading": "EV-71 related meningomyeloencephalitis",
    "id": "ev-71-related-meningomyeloencephalitis",
    "text": "Symptoms · Fever, vomiting, ataxia, myoclonic jerks (especially during sleep), CN dysfunction · Truncal hypotonia, limb weakness (AFM), urinary retention · Autonomic dysfunction + acute cardiorespiratory collapse o Arrythmias, pulmonary edema/hemorrhage Testing · LP · CSF EV testing- low sensitivity (27%) · EV rectum/throat/respiratory swab – high sensitivity (95%) o If no enterovirus is found, consider other possibilities (NMO, MOG, etc) · MRI WWO at least of brain; usually C/T spine as well o Sensitivity ~80% o Most commonly dorsal rhomboencephalitis with T2 hyperintensity encircling 4th ven"
  },
  {
    "section": "infectious-disease",
    "sectionName": "Infectious Disease",
    "heading": "Encephalitis",
    "id": "encephalitis",
    "text": "Consider the following studies in suspected encephalitis in US Children: Diagnostic ModalityTier 1 Tier 2 Common/Treatable CausesSelected Testing Dependent on Risk Factors / SituationUnexplained persistent or severe diseaseProceduresMRI Brain WWO +/- Spinal CordLumbar Puncture+/- EEGDilated ophtho examConsider repeat LPConsider brain biopsySerum TestingCBC, CRP, ESR or PCT, CMPHSV/EV PCR (neonate)+/- Bacterial CxWNV or other arboviral serologiesHIV AbsEBV or CMV serologiesAutoimmune encephalopathy panel CSF TestingCell count + Diff, glucose, proteinCultureMeningoencephalitis panelAutoimmune en"
  },
  {
    "section": "infectious-disease",
    "sectionName": "Infectious Disease",
    "heading": "COVID-19 and Neurologic Sequelae",
    "id": "covid-19-and-neurologic-sequelae",
    "text": "Multisystem Inflammatory Syndrome in Children (MIS-C): · An individual aged <21 years presenting with fever*, laboratory evidence of inflammation**, and evidence of clinically severe illness requiring hospitalization, with multisystem (>2) organ involvement (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic or neurological); AND · No alternative plausible diagnoses; AND · Positive for current or recent SARS-CoV-2 infection by RT-PCR, serology, or antigen test; or exposure to a suspected or confirmed COVID-19 case within the 4 weeks prior to the onset of symptoms. *Fever"
  },
  {
    "section": "neuro-exam",
    "sectionName": "Neuro Exam",
    "heading": "History:",
    "id": "history",
    "text": "Neurological Assessment: Introduction History- remember to ask   Include temporal pattern:  For paroxysmal episodes: How did it start? Any triggers? Postictal? i.e. if seizure started focally then generalized don’t just say “GTC”  Any changes: Acute; subacute or chronic? Age of onset of problem; Distinguish Developmental Delay from Regression Include full history of meds trialed, reason for switch and max dosing    Genetic History:  Miscarriages; early demise; “cerebral palsy”; consanguinity;  ethnicity(Ashkenazi?)    Metabolic Clues  Decompensations & dietary triggers, unusual odors (ie urine"
  },
  {
    "section": "neuro-exam",
    "sectionName": "Neuro Exam",
    "heading": "General Physical",
    "id": "general-physical",
    "text": "1. Height, weight, blood pressure, and head circumference. -Rule of thumb for head circumference is the 3 & 9 rule. AGEHC cmNewborn353 month 409 month453 yo509 yo55 2. General appearance, including dysmorphology. 3. Skin exam: neurocutaneous lesions (ash leaf spots (TS), cafe au lait spots (NF), angiomas (SW), axillary freckling (?), adenoma sebaceum (?), or shagreen patches (?). 4. Location of the hair whorl (can signify presence of cerebral malformations) and appearance of palmar creases (which genetic syndrome?) 5. Quality of scalp hair, eyebrows, and nails. Friable, kinky hair may signify"
  },
  {
    "section": "neuro-exam",
    "sectionName": "Neuro Exam",
    "heading": "Neurologic Examination of the Child",
    "id": "neurologic-examination-of-the-child",
    "text": "Neurological Exam There is no such thing as a “complete” neurological exam nor a patient too sick for neurological exam to be performed because:  Exam must be adjusted for age & situation (esp. newborn or coma) Exam typically includes rapid screen & focused testing based on presenting complaint and any deficits found on screen  What makes an exam adequate is whether it serves its goals:  Allows a differential diagnosis based on localization Determines what part of neuraxis may require imaging Sets an objective standard so other examiners will be able to tell if a deficit is new, improving or w"
  },
  {
    "section": "neuro-ophthalmology",
    "sectionName": "Neuro-Ophthalmology",
    "heading": "Vision Loss",
    "id": "vision-loss",
    "text": "Papillitis - Optic disc inflammation. May be unilateral. Papilledema - Optic disc edema specifically due to increased intracranial pressure. It is most often bilateral. Retrobulbar optic neuritis - Optic neuritis involving the optic nerve behind the globe. Depending on which part of the optic nerve is involved, papillitis may not be present. Neuroretinitis - Inflammatory process involving the optic discs with exudative changes in the nerve fiber layer of the retina (macular star). This is not associated with demyelinating disease."
  },
  {
    "section": "neuro-ophthalmology",
    "sectionName": "Neuro-Ophthalmology",
    "heading": "Vision Loss",
    "id": "vision-loss-2",
    "text": "Causes of acute vision lossCauses of progressive vision lossCarotid dissectionCortical blindness     Anoxic encephalopathy     Benign occipital epilepsy     Hydrocephalus     Hypoglycemia     Hypertension     Hyperviscosity     Hypotension     Migraine     Occipital metastatic disease     Posttraumatic transient cerebral blindness     SLE     Toxic     TraumaFunctional Neurological DisorderOptic neuropathy     Demyelinating        Idiopathic optic neuritis        Multiple sclerosis        NMO     Ischemia     Toxic     TraumaPituitary apoplexyPseudotumor cerebriRetinal disease    Central retin"
  },
  {
    "section": "neuro-ophthalmology",
    "sectionName": "Neuro-Ophthalmology",
    "heading": "Eye Abnormalities Associated with Specific Syndromes",
    "id": "eye-abnormalities-associated-with-specific-syndromes",
    "text": "CataractsGalactosemiaDown SyndromeHomocystinuriaLowe syndromeZellwegerRhizomelic chondrodysplasia punctataSenger SyndromeHypophosphatasiaEctopia LentisMarfan SyndromeTraumaHomocystinuriaMolybdenum cofactor deficiencySulfite Oxidase DeficiencyCherry Red Spot (seen at macula)Neimann-Pick Diseases A and BGaucher Disease type IIGM II Gangliosidosis (Tay Sachs and Sandhoffs)SialidosisFarber DiseaseCorneal CloudingMucopolysaccharidosesMucolipidosesLowe SydromeHomocystinuriaPigmentary Retinopathy Zellweger SyndromeNeonatal adrenoleukodystrophyLong chain 3-hydrocyacyl-CoA dehydrogenase deficiencyRetin"
  },
  {
    "section": "neuroradiology",
    "sectionName": "Neuroradiology",
    "heading": "General Reporting Structure",
    "id": "general-reporting-structure",
    "text": "Ventricles and CSF spacesBrain parenchymaWhite matterGray matter structuresExtra-axial spacesVascular structuresSkull base and cranial nervesSinuses and mastoids"
  },
  {
    "section": "neuroradiology",
    "sectionName": "Neuroradiology",
    "heading": "Sagittal T1 + Axial T1 (Review Structure/Anatomy)",
    "id": "sagittal-t1-axial-t1-review-structure-anatomy",
    "text": "Sagittal T1 - Focus on midline structures: Corpus callosum integrityBrainstem morphologyCerebellar vermis and tonsils (Chiari)Pituitary/pineal glandsVentricles (third, fourth, aqueduct)Craniovertebral junction Axial T1 - Focus on parenchyma and ventricles: Gray-white differentiationVentricle size and symmetryBasal ganglia and thalamiCortical surface/atrophyExtra-axial spacesVascular flow voids"
  },
  {
    "section": "neuroradiology",
    "sectionName": "Neuroradiology",
    "heading": "Axial T2 + Axial FLAIR",
    "id": "axial-t2-axial-flair",
    "text": "Axial T2 - Focus on signal abnormalities: White matter signalCSF spaces and ventriclesBasal ganglia and thalamiBrainstem signalVascular structuresSinuses and mastoids Axial FLAIR - Focus on pathologic hyperintensities: White matter lesions (periventricular, deep, subcortical)Cortical/subcortical junctionPeriventricular rimsSubarachnoid spaces (rule out SAH)Parenchymal lesions"
  },
  {
    "section": "neuroradiology",
    "sectionName": "Neuroradiology",
    "heading": "DWI + ADC",
    "id": "dwi-adc",
    "text": "DWI/ADC - Focus on restricted diffusion: Acute infarction (high DWI, low ADC)Subacute/chronic infarcts (T2 shine-through)Abscesses and cellular tumorsEpidermoid cystsSusceptibility artifacts"
  },
  {
    "section": "neuroradiology",
    "sectionName": "Neuroradiology",
    "heading": "SWI",
    "id": "swi",
    "text": "SWI/GRE - Focus on blood products: MicrohemorrhagesVascular malformationsHemorrhagic transformationCalcificationsIron depositionVenous anatomy"
  },
  {
    "section": "neuroradiology",
    "sectionName": "Neuroradiology",
    "heading": "Coronal T1/T2",
    "id": "coronal-t1-t2",
    "text": "Coronal T1/T2 - Focus on temporal structures: Hippocampi symmetry and signalTemporal lobes (mesial temporal sclerosis)Pituitary and cavernous sinusesOrbits and optic nervesVentricular morphology"
  },
  {
    "section": "neuroradiology",
    "sectionName": "Neuroradiology",
    "heading": "MRA",
    "id": "mra-2",
    "text": "Circle of Willis completenessMajor vessel patency (ICA, vertebral, basilar)Cerebral artery branchesAneurysmsVascular malformations"
  },
  {
    "section": "neuroradiology",
    "sectionName": "Neuroradiology",
    "heading": "1. Supratentorial Compartment",
    "id": "1-supratentorial-compartment",
    "text": "Cerebral hemispheres symmetryVentricle size and configurationWhite matter signal abnormalitiesGray matter morphologyBasal ganglia and thalamiCorpus callosum"
  },
  {
    "section": "neuroradiology",
    "sectionName": "Neuroradiology",
    "heading": "2. Infratentorial Compartment",
    "id": "2-infratentorial-compartment",
    "text": "Cerebellar hemispheresCerebellar pedunclesBrainstem (midbrain, pons, medulla)Fourth ventricleCisternal spaces"
  },
  {
    "section": "neuroradiology",
    "sectionName": "Neuroradiology",
    "heading": "3. Extra-axial Spaces",
    "id": "3-extra-axial-spaces",
    "text": "Subdural spacesSubarachnoid spacesBasal cisternsEpidural spaces"
  },
  {
    "section": "neuroradiology",
    "sectionName": "Neuroradiology",
    "heading": "4. Vascular Structures",
    "id": "4-vascular-structures",
    "text": "Major arterial flow voidsDural venous sinusesSuperficial and deep veinsEnhancement patterns (if contrast given)"
  },
  {
    "section": "neuroradiology",
    "sectionName": "Neuroradiology",
    "heading": "5. Skull Base and Adjacent Structures",
    "id": "5-skull-base-and-adjacent-structures",
    "text": "Craniovertebral junctionSkull base foraminaCranial nervesSinuses and mastoids"
  },
  {
    "section": "neuroimmunology",
    "sectionName": "Neuroimmunology",
    "heading": "Pediatric White Matter Changes",
    "id": "pediatric-white-matter-changes",
    "text": "Pediatric White Matter Changes (things to think about – although some of these are exceptionally rare and do not come up often) EndocrineThyroid disorder, diabetes mellitusInflammatorySLE, neurosarcoidosis, Sjogrens, APLAS, Behcet disease, Primary angiitis of the CNS MitochondrialMERRF, MELAS, LHON, Leigh, Kearns-SayreLeukodystrophyMetachromatic leukodystrophy, adrenoleukodystrophy, Krabbe, Pelizaeus-Merzbacher, Refsum, Vanishing White Matter, Leukoencephalopathy with brainstem and SC involvement & elevated lactate, Wilsons, Fabry, AlexanderGenetic/MetabolicInborn errors of metabolism, aminoac"
  },
  {
    "section": "neuroimmunology",
    "sectionName": "Neuroimmunology",
    "heading": "Autoimmune Encephalitis",
    "id": "autoimmune-encephalitis",
    "text": "Useful reference: “Likely Immune-Mediated Epilepsy/Encephalitis Syndromes” (LIMES)"
  },
  {
    "section": "neuroimmunology",
    "sectionName": "Neuroimmunology",
    "heading": "Anti-NMDA Encephalitis",
    "id": "anti-nmda-encephalitis",
    "text": "Epidemiology: 40% of all patients are younger than 18 yr, uncommonly associated with teratoma in young children.   Clinical: Psychiatric: hallucinations, paranoia, temper tantrums, episodic agitation Movement d/o: chorea, oromotor dyskinesias Speech reduction/mutism Seizures Autonomic instability – ↑HR, hypertension, hypoventilation, enuresis Sleep disturbance – wake frequently throughout the night – insomnia is seen often"
  },
  {
    "section": "neuroimmunology",
    "sectionName": "Neuroimmunology",
    "heading": "Evaluation:",
    "id": "evaluation",
    "text": "MRI Brain with and without contrastLP with cell count, protein, glucose, OCBs, CSF peds autoimmune CNS disorders panel Serum studies: consider CSF peds autoimmune CNS disorders panel and alternative causes of encephalopathy, movement d/o, etc.EEG if concerned for seizure.  Some interictal EEG patterns are thought to support the diagnosis (new onset epileptic encephalopathy – slowing and multifocal discharges in previously normal child, extreme delta brush - more in adults).Abdominal/pelvic MRI/US or testicular US to r/o teratoma.   Diagnostic Criteria (Graus 2016) Probable anti-NMDA receptor e"
  },
  {
    "section": "neuroimmunology",
    "sectionName": "Neuroimmunology",
    "heading": "Treatment:",
    "id": "treatment",
    "text": "Acute: Typically includes high dose methylprednisolone followed by IVIG or PLEX (3-5 days).  Refractory patients have been treated with Cyclophosphamide.Maintenance: Rituximab treatment typically q week x4 doses (started shortly after IVIG/PLEX) then every 6 months for two yearsSymptomatic: ASM if seizures, usually PT, OT, ST, maybe Rehab. Good to have School specialist +/- Neuropsych involved. Psychiatry consult is usually needed for agitation, hallucinations, catatonia, or sleep. (Patients are typically very sensitive to antipsychotics, higher risk of EPS)."
  },
  {
    "section": "neuroimmunology",
    "sectionName": "Neuroimmunology",
    "heading": "Prognosis:",
    "id": "prognosis",
    "text": "80% have substantial to full recovery.Anti-NMDAR Encephalitis One-Year Functional Status (NEOS) score (including intensive care unit admission, treatment delay >4 weeks, lack of clinical improvement within 4 weeks, abnormal MRI, and CSF white blood cell count >20 cells/μL) is useful for prognosticationSeizures usually remit after the encephalitis and other symptoms get under better controlUp to 20% recurrence rate in childrenIf treatment refractory or relapsing, think about further evaluation for teratoma (including extra-pelvic)   References:  Balu R, McCracken L, Lancaster E, Graus F, Dalmau"
  },
  {
    "section": "neuroimmunology",
    "sectionName": "Neuroimmunology",
    "heading": "Epidemiology:",
    "id": "epidemiology",
    "text": "Para-infectious 47% Post-vaccination 28%Age: (two peaks) below age 3, and between 5 and 17 yo"
  },
  {
    "section": "neuroimmunology",
    "sectionName": "Neuroimmunology",
    "heading": "Clinical Presentation:",
    "id": "clinical-presentation",
    "text": "Presentation with sensory, motor, or autonomic dysfunction (bowel, bladder, etc) attributable to the spinal cord, sensory levelSevere impairment during illness (89% non-ambulatory; bladder catheterization in 82%)Progression to nadir between 4 hours and 21 days of symptom onset   Differential:  NMO, MOG, rheumatologic (see MS work-up below), hypercoagulable state/spinal cord infarct (see hypercoag work-up in stroke section). More rare: HIV, Leigh, ANCA vasculitidies"
  },
  {
    "section": "neuroimmunology",
    "sectionName": "Neuroimmunology",
    "heading": "Evaluation:",
    "id": "evaluation-2",
    "text": "MRI brain and C/T spine with and without contrastCSF studies: basic studies + OCBs --- viral studies to consider (HSV, EBV, enterovirus, or MEP). Lyme if travel to East coast.Pleocytosis in 50%Elevated protein in 48%OCBs <5% Serum NMO antibodySerum anti-MOG antibodyOther lab considerations: HIV, ANA panel, sarcoid, IgG index, TSH, B12, Vit D."
  },
  {
    "section": "neuroimmunology",
    "sectionName": "Neuroimmunology",
    "heading": "Treatment:",
    "id": "treatment-2",
    "text": "IV methylpred 30mg/kg (max 1g) x 5 days, consider PLEX for severe casesOral steroid taper if concern for NMO or MOGAD and labs are still pendingRefractory – Consider ritux or cyclophosphamide"
  },
  {
    "section": "neuroimmunology",
    "sectionName": "Neuroimmunology",
    "heading": "Prognosis:",
    "id": "prognosis-2",
    "text": "Mortality / Morbidity2 of 47 diedComplete sphincter control in 46%Complete locomotion in 67% Better functional outcome if: older age, shorter time to dx, lower/fewer levels, no acute T1 hyperintensity, no pleocytosis Recurrence Risk of MS: one of 47 patients with a mean follow up of 8 years90% monophasic; the 10% that were not usually had underlying diagnosis of SLE, NMO, ADEM   Reference: Pidcock FS, Krishnan C, Crawford TO, et al. Acute transverse myelitis in childhood: center-based analysis of 47 cases. Neurology 2007; 68:1474–1480"
  },
  {
    "section": "neuroimmunology",
    "sectionName": "Neuroimmunology",
    "heading": "Clinical Presentation:",
    "id": "clinical-presentation-2",
    "text": "Age: Several months to 16 years, although usually < 11 yPreceding eventsNon-specific URI, GI illness, or other febrile illness – 53%Immunization (measles/pertussis) – 12%No prodrome – 26%Presenting featuresEncephalopathy (part of diagnostic criteria) Long tract signs, ataxia, cranial nerve palsy, seizures, meningeal reaction, optic neuritis, and extrapyramidal signs may be seen"
  },
  {
    "section": "neuroimmunology",
    "sectionName": "Neuroimmunology",
    "heading": "Diagnostic Criteria (IPMSSG 2007)",
    "id": "diagnostic-criteria-ipmssg-2007",
    "text": "Monophasic ADEM Clinical Criteria First clinical event with presumed inflammatory of demyelinating cause with acute or subacute onset that affects multifocal areasNo history or concern for prior demyelinating eventNo other etiologies can explain the eventMust be polysymptomatic and must include encephalopathyBehavioral change (confusion or excessive irritability)Alteration in consciousness (lethargy, coma)Within the next 3 months, new or fluctuating symptoms, signs, or MRI occur within 3 months of the inciting ADEMEvent should be followed by improvement, either clinically or on MRI, although d"
  },
  {
    "section": "neuroimmunology",
    "sectionName": "Neuroimmunology",
    "heading": "Evaluation:",
    "id": "evaluation-3",
    "text": "Serum: Anti-MOG, anti-NMO40% with anti-MOG antibodies; persistence at 6 months correlated with recurrenceRecurrent ADEM or recurrent ON after ADEM may be a variant of MOGMRI Brain with and without contrastMultifocal bilateral, asymmetric FLAIR hyperintensities in cerebral WM, basal ganglia, brainstem, cerebellum, thalami, or spinal cordEnhancement in 30%, open ringLP with cell count, diff, protein, glucose, OCBs, MEPPleocytosis or elevated protein in 28%OCBs can be positive up to 25% in casesConsider CSF anti-MOG if other signs concerning for MOGAD, but serum is negative"
  },
  {
    "section": "neuroimmunology",
    "sectionName": "Neuroimmunology",
    "heading": "Treatment:",
    "id": "treatment-3",
    "text": "Steroids: IV methylprednisolone 30 mg/kg/day (max 1g) qday for 3-5 days.  If concern for NMO or MOG and labs are still pending, follow with  prednisone of 1 mg/kg/day x 10 days, then slow 4-6 week taper.  No taper if suspected CIS (MS spectrum)."
  },
  {
    "section": "neuroimmunology",
    "sectionName": "Neuroimmunology",
    "heading": "Prognosis:",
    "id": "prognosis-3",
    "text": "Generally excellentHemiparesis (mild to severe) – 8%Partial epilepsy – 6%“Mental Handicap” – 4%10% of patients had relapse within 3 years +/- 2 years. All of these had negative OCBs. Unclear if “recurrent or multiphasic ADEM” is actually anti-MOG disease   Reference:  Tenembaum et al. 2002. Neurology. 59:1224-1231. Tenembaum et al. 2007. Neurology. 68 (Suppl 2): S23-S3"
  },
  {
    "section": "neuroimmunology",
    "sectionName": "Neuroimmunology",
    "heading": "Inflammatory Disorders Associated with OCBs",
    "id": "inflammatory-disorders-associated-with-ocbs",
    "text": "MS – 98% (Generally is >=4 OCBs)NMO – 18%MOG – 11%Neuro-SLE – 50%Neuro-Behcet’s – 20%Neurosarcoidosis – 5-33% Other causes of +OCBsNeuro-infections - Neurosyphilis, Neuro-HIV, Neuro-lyme, SSPENeuro-genetic/metabolic - ataxia-telangiectasia, adrenoleukodystrophy, cerebral folate deficiencyRule of thumb for intermediate findings: 2 OCBs is not clearly inflammatory (higher false positive for non-inflammatory things), 3 OCBs is likely incidental unless the clinical symptoms fit a disease associated with OCBs, and if 4 OCBs, would consider if immunotherapy trial is warranted"
  },
  {
    "section": "neuroimmunology",
    "sectionName": "Neuroimmunology",
    "heading": "Diagnosis:",
    "id": "diagnosis",
    "text": "2017 Revised McDonald Criteria To diagnose MS, you need BOTH dissemination in time AND dissemination in spaceAlso reasonable exclusion of other causes “no better explanation for the clinical presentation”   Dissemination in Time Criteria 2 or more clinical attacks OR  1 clinical attack PLUS one of the following Additional clinical attackMRI showing simultaneous contrast enhancing and non-contrast enhancing lesionsFollow-up MRI showing new T2 lesion or new contrast enhancementPresence of oligoclonal bands   Dissemination in Space Criteria 2 or more lesions with objective clinical evidence OR On"
  },
  {
    "section": "neuroimmunology",
    "sectionName": "Neuroimmunology",
    "heading": "Evaluation:",
    "id": "evaluation-4",
    "text": "MRI brain with and without contrast, consider spinal imaging if myelopathic symptomsMimics: LP with cell count/diff, IgG Index, OCBs (serum and CSF drawn at same time in the lab), ANA profile, ACE (if concern for sarcoid), HIV Ab/Ag, NMO, MOGVitamin DFor DMARD initiation labs (Ritux or Gilenya): preg test (post-pubertal females), CBC, CMP, JCV Ab (send out to Quest), TB QuantiFERON PLUSFor Ritux initiation: Hep B core +surface ab/Ag, Hep C total antibodies, immunoglobulin panel (IgG, IgM, IgA), anti-CD20 monitoring panelFor Gilenya: ophtho eval with OCTs, VZV serologies (vaccinate prior to st"
  },
  {
    "section": "neuroimmunology",
    "sectionName": "Neuroimmunology",
    "heading": "Treatment:",
    "id": "treatment-4",
    "text": "Acute Flares:Ensure not a pseudo flare: Look-for infectious causes, stress-related triggers (symptoms usually the same as prior flares, and lasting <24 hours)IV methylprednisolone 30mg/kg/day (max 1g) q24 hours for 3-5 days; no taperCan sometimes be arranged through the infusion center instead of admission, or may use very high dose oral pred (up to 1250mg/day, not for first dose or severe presentation, sometimes difficult to do – 25 pills)GI prophylaxisChronic/Disease Modifying Therapies (DMTs)Vit D supplementation (goal levels 40-80)Many different DMTs available, the ones given here are the"
  },
  {
    "section": "neuroimmunology",
    "sectionName": "Neuroimmunology",
    "heading": "Epidemiology:",
    "id": "epidemiology-2",
    "text": "Age  teens to 30sMore likely to be bilateral in kids < 10 yo"
  },
  {
    "section": "neuroimmunology",
    "sectionName": "Neuroimmunology",
    "heading": "Clinical Presentation:",
    "id": "clinical-presentation-3",
    "text": "Progresses over days to 2 weeks90% with pain (usually with eye movements due to stretching of the sheath)Red desaturation (difficulty with night vision)Really all colors, but red especiallyRAPD (non specific for ON)Optic disc edema - loss of margins over the superior and inferior parts of the disc (one of the first signs).  Optic disc hyperemia2/3 are RETRObulbar, and might look normalCentral scotoma usually (although can be anything)     Differential: Autoimmune - ADEM, MS, NMO, MOG, Sjogren’s, Sarcoidosis, SLE, APLAIdiopathicOther causes / mimicsOptic glioma (NF1)Retinal ischemiaIncreased IC"
  },
  {
    "section": "neuroimmunology",
    "sectionName": "Neuroimmunology",
    "heading": "Evaluation:",
    "id": "evaluation-5",
    "text": "Get orbital MRI WWO if trying to evaluate ON (thin slices, T1 fat desat signals with gad)95% sensitive for ON, but not 100% (still a clinical diagnosis)Look at coronal slices with T1+POST for enhancementLook at STIR - normally, should see nerve as dark with bright signal surrounding itMRI Brain will miss ON 70% of the time (only 30% sensitive), due to a different protocol from the Orbits protocolMRI Brain WWO may assist in determining if part of a broader demyelinating syndromeSerum anti-NMO and anti-MOG, LP with basic studies and OCBsR/o mimics if appropriate, or with risk factors for this (c"
  },
  {
    "section": "neuroimmunology",
    "sectionName": "Neuroimmunology",
    "heading": "Treatment:",
    "id": "treatment-5",
    "text": "High dose steroids (IV methypred 30/kg max 1 g) x 3 days, followed by 11 days oral pred (1mg/kg/day), then short oral pred taper. No oral steroids if related to MS.Although this is the protocol used in the Optic Neuritis Treatment Trial, no good data for or against a steroid taper is present. If NMO or MOG is strongly suspected, consider continuing daily prednisone until antibody result is known. In ONTT, accelerated visual recovery (especially visual field defects) BUT did not improve visual outcomes at 6 months to 1 year (slightly better visual fields, contrast / color sensitivity, but simil"
  },
  {
    "section": "neuroimmunology",
    "sectionName": "Neuroimmunology",
    "heading": "Prognosis:",
    "id": "prognosis-4",
    "text": "Visual recovery>80% of children had full visual recovery, some with recovery within 2-3 weeksIF NOT RECOVERING within a couple weeks, have higher suspicion for NMO, sarcoidosis, or one of the non-demyelinating causesWorse prognostic signs (also consider alternative causes):Clinical worsening after 2 weeks, NMO, recurrent optic neuritis, less than 20/50 vision at 4 weeksRisk of MS36% risk of progressing to MS within 2 yearsLess of a risk to go to MS if < 10 yo or >40 yoMore of a risk if bilateral, or OCBs presentLess of a risk if normal MRI at presentation, or if <10 yoRisk of relapse of ON – 3"
  },
  {
    "section": "neuroimmunology",
    "sectionName": "Neuroimmunology",
    "heading": "Neuromyelitis Optica Spectrum Disorder (NMOSD)",
    "id": "neuromyelitis-optica-spectrum-disorder-nmosd",
    "text": "Diagnosis: NMOSD (International Consensus Criteria) Diagnostic Criteria for NMOSD with AQP4-IgGAt least 1 core clinical characteristicPositive test for AQP4-IgG using best available detection method (cell-based assay strongly recommended)Exclusion of alternative diagnosesDiagnostic Criteria for NMOSD without AQP4-IgG or unknown statusAt least 2 core clinical characteristics occurring as a result of one or more clinical attacks and meeting all of the following requirements:At least 1 core clinical characteristic must be optic neuritis, acute myelitis with LETM, or area postrema syndromeDissemin"
  },
  {
    "section": "neuroimmunology",
    "sectionName": "Neuroimmunology",
    "heading": "Evaluation:",
    "id": "evaluation-6",
    "text": "MRI Brain and Orbits with and without contrast (with fat saturation for better evaluation of optic nerves) – may see optic nerve enhancement, may see symmetric hypothalamic or thalamic, periaqueductal grey, or large hemispheric WM lesions (no Dawson’s fingers)MRI C/T/L spine with and without contrast (Can sometimes do C/T spine on small patients if you can visualize conus medullaris – check with rads)Serum NMO is 78 % sensitive and 100% specific but may not be positive on initial testing in up to 12% of patients (re-test in 6 months if high suspicion) – test on un-treated serum/CSF if possible"
  },
  {
    "section": "neuroimmunology",
    "sectionName": "Neuroimmunology",
    "heading": "Treatment:",
    "id": "treatment-6",
    "text": "Acute:IV methylprednisolone 30mg/kg/day (max 1g) q24 hours for 3-5 daysGI prophylaxisLow threshold for PLEX and/or eculizumab if transverse myelitis, or refractory to steroidsIVIG not typically used in this setting unless refractory to steroids + PLEXLong term tx – immunosuppression typically required.Rituximab most often, but recently ineblizumab (anti-CD19) in adults may be more effective. Also, can use azathioprine, mycophenolate, methotrexate, eculizumab, or satralizumab/tocilizumab (IL6 inhibitor)No strict consensus on best long-term treatmentUsually continued for several years if NMO Ab+"
  },
  {
    "section": "neuroimmunology",
    "sectionName": "Neuroimmunology",
    "heading": "Prognosis:",
    "id": "prognosis-5",
    "text": "Stepwise deterioration due to accumulating symptomsRelapses occur in over 90% of patientsVisual disability higher with NMO than with idiopathic or MS-related ONHigh change of other systemic autoantibody diseases – SLE, Sjogren’s, etcPredictors of worse prognosis– number of relapses within the first two years, severity of first attack, older age at onset, association with other auto-immune diseases, +NMO antibody   References:  Jarius S, Wildemann B, Paul F. Neuromyelitis optica: Clinical features, immunopathogenesis and treatment. Clin Exp Immunol Published Online First: 2014. doi:10.1111/cei."
  },
  {
    "section": "neuroimmunology",
    "sectionName": "Neuroimmunology",
    "heading": "Clinical Presentation:",
    "id": "clinical-presentation-4",
    "text": "Optic neuritis (54%, bilateral in 32%)Myelitis (18-23%)ON + spinal cord involvement (especially thoracolumbar)More in male teens or adultsADEM-like in kids (20%), leukodystrophy-like presentations (antibody might be generated secondary to neurodegeneration)Brainstem encephalitis (8-14%)Seizures may occur in kids (more often than in NMO)Can present as FLAMES: FLAIR hyperintense lesions in anti-MOG encephalitis with seizures    Diagnostic Criteria (per consensus paper 2023, must meet all 3 criteria): Core clinical demyelinating event: Optic neuritis, myelitis, ADEM, cerebral monofocal or polyfoc"
  },
  {
    "section": "neuroimmunology",
    "sectionName": "Neuroimmunology",
    "heading": "Evaluation:",
    "id": "evaluation-7",
    "text": "Serum - Anti-MOG, anti NMO, peds autoimmune CNS panelLPMajority have a pleocytosis, may have neutrophilicOCBs - uncommon (11%)Consider Quest CSF Anti-MOG if high suspicion but serum testing negativeMRI findingsMay be very similar to NMOSD in appearanceHigh prevalence of LETMLess striking contrast enhancement compared to ADEM?Can see leptomeningeal enhancement/thickeningSupratentorial MRI lesions (35%)ON (including bilateral ON) Even if only clinically unilateral, often subclinical atrophy of the other nerveBrainstem lesions (pons / adjacent to 4th ventricles), bilateral - 30% of patients\"Fluff"
  },
  {
    "section": "neuroimmunology",
    "sectionName": "Neuroimmunology",
    "heading": "Treatment:",
    "id": "treatment-7",
    "text": "AcuteIV methylprednisolone x 5 days, and oral pred taper over 4 weeksPLEX if severe presentationConsider tocilizumab also if severeLong term (consider if recurrent relapses, continue for ~12-24 months)If relapse while weaning steroids, consider just upping the steroids again and slowing weanIf relapse 30+ days after steroids are weaned:IVIG - regular dosing (2g/kg over 3 days to start, then 1g/kg every 4 weeks afterwards) – may be most effective strategy for recurrent anti-MOGRituximab - 30-50% response rate (much lower than other diseases)Tocilizumab (recurrent disease refractory to IVIg)"
  },
  {
    "section": "neuroimmunology",
    "sectionName": "Neuroimmunology",
    "heading": "Prognosis:",
    "id": "prognosis-6",
    "text": "Rare to have co-existing autoimmune diseasesMulti-phasic course in 80%, annualized relapse rate of 0.9Higher risk if concurrent OCBs, or persistent anti-MOG over 3-6 months1/3 of patients with ON and 1/2 of patients with myelitis made full recoveries   Reference:  Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP, Ramanathan S, Waters P, Tenembaum S, Graves JS, Chitnis T, Brandt AU, Hemingway C, Neuteboom R, Pandit L, Reindl M, Saiz A, Sato DK, Rostasy K, Paul F, Pittock SJ, Fujihara K, Palace J. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: Inte"
  },
  {
    "section": "neuroimmunology",
    "sectionName": "Neuroimmunology",
    "heading": "Clinical Presentation:",
    "id": "clinical-presentation-5",
    "text": "Upper and lower facial weaknessHyperacusisTaste change\"increased\" tearing – actually decreased production, but just not clearing tears wellDifficulty closing eye fully, leading to asymmetric blinkPain behind the ear (small sensory component)   Differential / Causes: Idiopathic (Bell’s Palsy)HSV/VZVLyme (most common cause in locations with endemic Lyme)OtomastoiditisTrauma, post-surgicalRare: Schwannoma or other compressive tumor, neuropsychiatric lupus, leukemia   Treatment (if within 3 days of presentation): 1mg/kg/day (max 60mg/day) x 5 days +/- 5 day taper1 mg/kg/day as effective as 2 mg/kg"
  },
  {
    "section": "neuroimmunology",
    "sectionName": "Neuroimmunology",
    "heading": "Prognosis:",
    "id": "prognosis-7",
    "text": "May worsen for a few weeks, then plateau/improve around week 3. Recovery over months to 1 year>90% with complete recovery by 6 monthsConsider referral for nerve grafting if not having good progress after 6 weeks. Consider evaluation for other causes of facial nerve paralysis (imaging, etc)5% may develop facial synkinesis (“crocodile tears”, or eye blink whenever smiling)   References:  Arican P, Dundar NO, Gencpinar P, et al. Efficacy of Low-Dose Corticosteroid Therapy Versus High-Dose Corticosteroid Therapy in Bell’s Palsy in Children. J Child Neurol 2017;32:72–5.   Babl FE, et al; Paediatric"
  },
  {
    "section": "neuroimmunology",
    "sectionName": "Neuroimmunology",
    "heading": "Epidemiology:",
    "id": "epidemiology-3",
    "text": "Before VZV vaccine, 50% were VZV-relatedCan be post-vaccination or any number of post-viral causes; several days to several weeks afterAge generally < 6 yo, but can be seen into adolescence"
  },
  {
    "section": "neuroimmunology",
    "sectionName": "Neuroimmunology",
    "heading": "Clinical Presentation:",
    "id": "clinical-presentation-6",
    "text": "Cerebellar ataxia: In kids, first sign may be refusal to walk. May also have gait/truncal ataxia, dysmetria, intention tremor, nystagmus, speech changes, vomiting, or headacheCerebellitis: May see encephalopathy, mutism, persistent headache (hydrocephalus), or focal signs (brainstem compression), fever, meningismus"
  },
  {
    "section": "neuroimmunology",
    "sectionName": "Neuroimmunology",
    "heading": "Evaluation:",
    "id": "evaluation-8",
    "text": "R/o other causes of acute ataxia if indicated by history (ingestion, metabolic work-up if recurrent, stroke, mass, Miller-Fisher, opsoclonus-myoclonus, etc) – LP, MRI, Utox/ethanol, etcIf <3 days from onset, and <3 yo, neuroimaging yield is <1%If >3 days of sx, older child, or with focal signs, encephalopathy, persistent headache: neuroimaging to rule out cerebellitis or other cause of ataxiaLP, if performed, shows a predominantly lymphocytic pleocytosis in ~50%. OCBs present in 10-17%"
  },
  {
    "section": "neuroimmunology",
    "sectionName": "Neuroimmunology",
    "heading": "Treatment:",
    "id": "treatment-8",
    "text": "Cerebellar ataxia: supportive care, PTCerebellitis: Controversy on steroids, but most case series have used 10-14 days of steroids (initially dexamethasone, transition to pred taper after several days) – may decrease swelling, surgical need, long-term morbidityIf hydrocephalus, may need neurosurgical managementSupportive care, PT/OT/SLP/Rehab"
  },
  {
    "section": "neuroimmunology",
    "sectionName": "Neuroimmunology",
    "heading": "Prognosis:",
    "id": "prognosis-8",
    "text": "Cerebellar ataxia improves over 2-3 weeks to months, with only 10% with mild residual deficitsCerebellitis recovery takes months to a year, with 14% with residual motor/speech deficits at 1 year. Higher risk of mortality from consequences of swelling. MRI findings do not accurately predict level of permanent injury.   References:  Desai J, Mitchell WG. Acute Cerebellar Ataxia , Acute Cerebellitis , and Opsoclonus-Myoclonus Syndrome. 2012;27:1482–8.    Rudloe T, Prabhu SP, Gorman MP, et al. The Yield of Neuroimaging in Children Presenting to the Emergency Department with Acute Ataxia in the Pos"
  },
  {
    "section": "headaches",
    "sectionName": "Headaches",
    "heading": "Treatments",
    "id": "treatments-2",
    "text": "Headache acute meds  Medication Form Dosage Max Freq SE Ibuprofen PO 10 mg/kg/dose 800 mg Q 6-8 h GI bleed Ketorolac (Toradol) PO IV/IM Greater than 50 kg: 10-30 mg Less than 50 kg: 0.5 mg/kg/dose 30 mg 15 mg Q 6-8 h Q 6-8 h GI bleed, decr plt fxn Naproxen PO 10 mg/kg/dose 500 mg Q 12 h GI Bleed, drowsy, dec plts Acetaminophen PO/PR 15 mg/kg/dose 450-650 mg Q 4-6 h Hepatic toxicity Metoclopramide (Reglan) PO/IV/IM 0.1- 0.15 mg/kg/dose 10 mg Q 6 h anxiety, diarrhea leucopenia, dystonic reaction Promethazine (Phenergan) PO/IM/ IV/PR 0.25-1 mg/kg/dose 25 mg Q 4-6 h blurred vision, dystonic rxn Pr"
  },
  {
    "section": "headaches",
    "sectionName": "Headaches",
    "heading": "Migraine without aura",
    "id": "migraine-without-aura",
    "text": "Classification: A. At least 5 attacks fulfilling B-D, not attributable to another cause  B. Headache lasting 2-72 hours (4hrs in adults)  C. Headache has > 2 of the following  a. Unilateral or bilateral (must be unilateral in adults)  b. Pulsating quality  c. Moderate- Severe  d. Aggravated by movement  D. Headache has >1 of the following  a. Nausea or vomiting  b. Photo AND phonophobia"
  },
  {
    "section": "headaches",
    "sectionName": "Headaches",
    "heading": "Tension-Type",
    "id": "tension-type",
    "text": "At least ten attacks fulfilling criteria A-C  A. Headache attacks lasting 30 minutes to 72 hours (untreated or unsuccessfully treated)  B. Headache attack has at least two of the following characteristics:  a. Bilateral location b. Band/pressure quality c. mild to moderate pain d. not aggravated by routine physical activity  C. During headache:  a. no nausea or vomiting b. photophobia OR phonophobia  D. Not attributed to another disorder"
  },
  {
    "section": "headaches",
    "sectionName": "Headaches",
    "heading": "Migraine with brainstem aura (Basilar type migraine)",
    "id": "migraine-with-brainstem-aura-basilar-type-migraine",
    "text": "Classification: A. At least 2 attacks fulfilling criteria B-D B. Aura consisting of visual, sensory, and or speech language symptoms, each fully reversible, but no motor or retinal symptoms C. at least two of the brainstem symptoms: 1. Dysarthria, 2. Vertigo, 3. Tinnitus, 4. Hypacusia, 5. Diplopia, 6. Ataxia 7. decreased level of consciousness D. At least two of the following: 1. at least one aura symptom develops gradually over ≥5 minutes and/or different aura symptoms occur in succession over ≥5 minutes. 2. each aura symptom lasts 5-60 minutes, motor symptoms last less than 72 hours.  3. at"
  },
  {
    "section": "headaches",
    "sectionName": "Headaches",
    "heading": "Abdominal Migraine",
    "id": "abdominal-migraine",
    "text": "Abdominal pain not accompanied by migraine headache Diagnostic criteria include at least five attacks fulfilling criteria A-C:  Pain has at least two of the following three characteristics:   Midline location, periumbilical, or poorly localized Dull or “just sore” quality  Moderate or severe intensity   During attacks, at least two of the following:  Anorexia NauseaVomitingPallor Attacks last 2 to 72 hours when untreated or unsuccessfully treated  Complete freedom from symptoms between attacks  Not attributed to another disorder  GI workup negative"
  },
  {
    "section": "headaches",
    "sectionName": "Headaches",
    "heading": "Chronic Headaches",
    "id": "chronic-headaches",
    "text": "Both migraines and tension-type headaches can become chronic, meaning that they occur at least 15 days per month for greater than 3 months  Chronic headaches can result from taking some types of medication—for example, acetaminophen (Tylenol), ibuprofen (Motrin), caffeine, and some prescription medications—almost every day. These are called medication overuse headaches. The most effective way to make these headaches better is to stop taking pain medicines altogether for 2 to 3 weeks. After that time, use of pain-relievers is limited to no more that 2 to 3 times per week."
  },
  {
    "section": "headaches",
    "sectionName": "Headaches",
    "heading": "Hemiplegic Migraine",
    "id": "hemiplegic-migraine",
    "text": "Classification A. At least 2 attacks fulfilling criteria B and C B. Aura consisting of both of the following 1. fully reversible motor weakness 2. fully reversible visual, sensory and or speech/language symptoms C. At least two of the following: 1. at least one aura symptom develops gradually over ≥5 minutes and/or different aura symptoms occur in succession over ≥5 minutes 2. each aura symptom lasts 5-60 minutes, motor symptoms last less than 72 hours.  3. at least one aura symptom is unilateral 4. The aura is accompanied or followed within 60 minutes by a headache Familial Hemiplegic Migrain"
  },
  {
    "section": "headaches",
    "sectionName": "Headaches",
    "heading": "New Daily Persistent Headache",
    "id": "new-daily-persistent-headache",
    "text": "Classification: A. Headache that, within 3 months of onset, fulfils criteria B-D B. Headache is present daily, and is unremitting, for >3 months C. At least two of the following pain characteristics: 1. bilateral location 2. pressing/tightening (non-pulsating) quality 3. mild or moderate intensity 4. not aggravated by routine physical activity such as walking or climbing D. Both of the following: 1. no more than one of photophobia, phonophobia or mild nausea 2. neither moderate or severe nausea nor vomiting Diagnostic work up (focus on ruling out secondary causes)   MRI/MRV with and without co"
  },
  {
    "section": "headaches",
    "sectionName": "Headaches",
    "heading": "Hemicrania Continua",
    "id": "hemicrania-continua",
    "text": "Classification: A. Headache for >3 months fulfilling criteria B-D B. All of the following characteristics: 1. unilateral pain without side-shift 2. daily and continuous, without pain-free periods 3. moderate intensity, but with exacerbations of severe pain C. At least one of the following autonomic features occurs during exacerbations and ipsilateral to the side of pain: 1. conjunctival injection and/or lacrimation 2. nasal congestion and/or rhinorrhoea 3. ptosis and/or miosis D. Complete response to therapeutic doses of indomethacin Indomethacin Protocol Typical adolescent dosing. If less tha"
  },
  {
    "section": "headaches",
    "sectionName": "Headaches",
    "heading": "Idipathic Intracranial Hypertension (pseudotumor cerebri)",
    "id": "idipathic-intracranial-hypertension-pseudotumor-cerebri",
    "text": "Diagnosis via modified Dandy Criteria:  Signs and symptoms of increased intracranial pressure (some or all may be present)Headache worse with laying flat or coughing, straining – can be progressiveTransient visual obscurationsPulsatile tinnitusNormal neurologic exam with the exception of the following (which may or may not be present):PapilledemaEnlarged blind spotCN VI palsyCSF opening pressure >28 cm H2O without cytologic abnormalities (low CSF protein okay) – OP will be higher in peds (~28cm H2O)MRI of the brain without any intracranial pathology (including lack of cerebral sinus venous thr"
  },
  {
    "section": "headaches",
    "sectionName": "Headaches",
    "heading": "Headache Red Flags (Consider Imaging)",
    "id": "headache-red-flags-consider-imaging",
    "text": "Focal neurologic deficit Young age (less than 8 years old) Posteriorly-located headache – if migraine symptoms increase and neuro exam normal, not a tumorNew onset or worsening headache that is not a migrainePostural headache Nighttime awakening headache and or vomiting Early morning headache and or vomiting Neurocutaneous stigmata  ** Note - >95% of children with intracranial mass will have objective neurologic findings"
  },
  {
    "section": "headaches",
    "sectionName": "Headaches",
    "heading": "Emergency Headache Treatment",
    "id": "emergency-headache-treatment",
    "text": "A recent study of oral VPA tapers suggest there is likely no benefit in reducing migraine recurrence after treatment with IV VPA in the ED.            Citation: Rosenthal S, Mazzio E, Gilbert H et al. Efficacy of Intravenous Valproic Acid and Oral Valproic Acid Tapers for Treatment of Pediatric Headaches in the Emergency Department. Accepted for publication: Neurol Clin Pract. 2023     Status Migrainosus/Migraine Clinical Pathways for Emergency/UC and inpatient      Headache Clinical Pathway        INTRANASAL KETAMINE FOR STATUS MIGRAINOSUS Intranasal ketamine is an effective, safe treatment f"
  },
  {
    "section": "headaches",
    "sectionName": "Headaches",
    "heading": "Migraine Pathophysiology",
    "id": "migraine-pathophysiology",
    "text": "I"
  },
  {
    "section": "paroxysms",
    "sectionName": "Paroxysms",
    "heading": "Non-Epileptic Paroxysmal Events of Early Childhood",
    "id": "non-epileptic-paroxysmal-events-of-early-childhood",
    "text": "\"Funny\" or \"Weird\" Baby movements are among the most common consult questions.   In children between 6-10mo, the most common etiology is primary motor stereotypies. This is considered more likely if the movement is: Brief, lasting 1-2 secondsNo alteration in awareness/LOCOccur during times of excitement, anticipation, and other high emotional statesInvariably when seated in a high chair being fed (or entertained in a car seat or activity center) NB: can have dystonic character to phenomenology   Shuddering attacks are also common in infancy. Phenomenology is often described as a brief tremor o"
  },
  {
    "section": "paroxysms",
    "sectionName": "Paroxysms",
    "heading": "Breath-Holding Spells",
    "id": "breath-holding-spells",
    "text": "The most important approach is to reassure the family, because witnessing a breath-holding spell is a frightening experience for observers. There is no definitive treatment available or needed for breath-holding spells, as the child will eventually outgrow them. Some trials have demonstrated the efficacy of iron therapy, especially because although BHS can readily occur without anemia, BHS has been found to be exaggerated by the presence of anemia.[1][2] Other studies have supported the use of piracetam;[3][4] a 1998 study indicating that over two months piracetam reduced BHS incidence by sixt"
  },
  {
    "section": "paroxysms",
    "sectionName": "Paroxysms",
    "heading": "Seizure Mimics",
    "id": "seizure-mimics",
    "text": "Seizure Mimics in Adults Studies indicate that approximately 20% of patients presenting for evaluation of seizure are misdiagnosed as having epilepsy. Conditions most commonly mistaken for epileptiform seizure activity include syncope and psychogenic non-epileptic seizures.  Syncope: Syncope is a LOC due to decreased cerebral perfusion, resulting in loss of postural tone, with rapid return to mental status baseline. Syncope may be cardiac, orthostatic, or neurocardiogenic (vasovagal) in origin. Psychogenic Non-Epileptic Spell/Episode (PNES):  PNES, a condition characterized by the presence of"
  },
  {
    "section": "neurogenetics-and-neurometabolics",
    "sectionName": "Neurogenetics and Neurometabolics",
    "heading": "Malformations:",
    "id": "malformations",
    "text": "Classified, in part, based on point in Gestation when went awry (based on Aicardi 1992) Gestation(weeks)ProcessMajor Morphological CNS EventsCorresponding Disorders3-4Primary NeurulationNeural tube, neural crest & derivatives; closure of rostral & caudal neuroporesAnencephaly; encephalocele, myelomeningocele; Chiari malformation4-6TelencephalizationDev of forebrain & face; formation of cerebral vesicles; optic & olfactory placodes; fusion of cerebellar platesHoloprosencephaly; Dandy-Walker; craniosynostosis6-16Neuronal & Glial proliferationCell proliferation in ventricular and subventricular z"
  },
  {
    "section": "neurogenetics-and-neurometabolics",
    "sectionName": "Neurogenetics and Neurometabolics",
    "heading": "Neurocutaneous Disorders",
    "id": "neurocutaneous-disorders",
    "text": "Neurofibromatosis 1 (NF-1; von Recklinghausen’s syndrome)  Genetics: AD; chromosome 17   NF-1 Diagnostic CriteriaRequires > 2 of the followingParent with NF1Café au lait spots > 6     > 5 mm if pre-pubertal     > 15 mm if post-pubertal    2 NFs or one plexiform NF    Freckling in axillary/inguinal area    Optic glioma2 lisch nodules (pigmented iris hamartomas)Bony abnormality (sphenoid dysplasia, kyphoscoliosis)   NF-2: Associated with (bilateral) acoustic neuromas  AD, chromosome 22     Tuberous Sclerosis Complex Genetics: AD, TSC1 on 9q (hamartin) & TSC2 on 16p  (tuberin)Diagnosis is usually"
  },
  {
    "section": "neurogenetics-and-neurometabolics",
    "sectionName": "Neurogenetics and Neurometabolics",
    "heading": "Neuro-Metabolic Disorders",
    "id": "neuro-metabolic-disorders",
    "text": "Introductory Approach to Classic Neuro-Metabolic Disorders:  IEMs comprise a group of genetic disorders (AR or X-linked) causing clinically significant block in a metabolic pathway result in either accumulation of a substrate behind a block or a deficiency of the product.  May be classified by pathway, presentation, site of problem in neuro-axis, or under the following categories (detailed review below):  intoxication-type IEMs (e.g., AAs, OAs, urea cycle d/o), organelle disorders (e.g., paroxysmal, lysosomal, CDGs, nucleus/purines), energy failure disorders (mitochondrial, FA oxidation, Gut-1"
  },
  {
    "section": "neurogenetics-and-neurometabolics",
    "sectionName": "Neurogenetics and Neurometabolics",
    "heading": "Testing for Metabolic Disorders with Neurologic Presentations",
    "id": "testing-for-metabolic-disorders-with-neurologic-presentation",
    "text": "By Metabolic Test TestCategory of disordersUOA (N = 22 treatable IEMs)Organic Acidurias, Mitochondrial, Fatty Acid Oxidation, Aminoacidopathies QSAA (N = 13)Mitochondrial, Aminoacidopathies, Urea Cycle Lactate and Pyruvate Organic Acidurias, Mitochondrial Ammonia Organic Acidurias, Urea Cycle CK Mitochondrial, Myopathies, Muscular Dystrophies Plasma total Homocysteine (N = 9)Homocystinuria, Cobalamin C/D/E/F/G deficiency, MTHFR deficiencyUric Acid Mitochondrial, Fatty Acid Oxidation Disorders, Purine D/o Acylcarnitine Profile Organic Acidurias, Fatty Acid Oxidation Disorders VLCFA and Plasmalo"
  },
  {
    "section": "neurogenetics-and-neurometabolics",
    "sectionName": "Neurogenetics and Neurometabolics",
    "heading": "Intoxication-Type Inborn Errors of Metabolism",
    "id": "intoxication-type-inborn-errors-of-metabolism",
    "text": "Amino Acidopathies Impaired neuro function by toxic intermediates and decreased NT productionPresentations:Acute Neonatal encephalopathy, seizures, cerebral edemaGlobal Developmental Delays and DementiaLab markers: metabolic acidosis with ketosis; often elevated lactate, hyperammonemiaDysmorphology: may affect development of corpus callosumLocalization: early grey matter, later white matter myelinationCommon Disorders:Homocystinuria: clotting, lens dislocation, Marfan habitusMaple Syrup Urine Disease (MSUD; urine smells like burnt sugar)difficulty metabolizing branched chain AAs (Isoleucine, L"
  },
  {
    "section": "neurogenetics-and-neurometabolics",
    "sectionName": "Neurogenetics and Neurometabolics",
    "heading": "Organelle Disorders",
    "id": "organelle-disorders",
    "text": "Nucleus: Purine Disorders Purine biosynthesis generates AMP and GMPClinical Features:Renal: recurrent UTI, stones, failureNeurological: GDD, epilepsy, spasticity, dystonia, ataxia, autism, self-mutilation, deafnessArthritis, goutSmall statureMuscle cramps and wastingAnemiaImmunodeficiency with recurrent infectionsConditions: Lesch-Nyhan Testing: Serum uric acid & 24-hour urine uric acidUrine crystals (urate)Urine Purines and Pyrimidines Treatment: Purine-restricted dietAllopurinol Fluids   Golgi Complex: Congenital Disorders of Glycosylation Post-translation processing defect in Golgi where gl"
  },
  {
    "section": "neurogenetics-and-neurometabolics",
    "sectionName": "Neurogenetics and Neurometabolics",
    "heading": "Energy Failure Disorders",
    "id": "energy-failure-disorders",
    "text": "Mitochondrial Disorders Inheritance: mtDNA (maternal), AD or AR (either parent)100s of different disordersMultisystem presentations but especially involving high-energy organsBrain: migraines, sz, dementia, ataxia, dystonia, myoclonus, brainstem dysfunction, callosal malformationsPNS: ophthalmoplegia, hearing loss, retinal abnormalities, peripheral neuropathy, autonomic neuropathyGI: motility, absorptionCardiac: cardiomyopathy, rhythm abnormalitiesRenal: loss of AAHepatic: Hepatitis, Fatty InfiltrationPancreas: DiabetesMuscle: MyopathyStepwise Regressions triggered byFeverFastingInfection/Immu"
  },
  {
    "section": "neurogenetics-and-neurometabolics",
    "sectionName": "Neurogenetics and Neurometabolics",
    "heading": "Neurotransmitter Disorders",
    "id": "neurotransmitter-disorders",
    "text": "Clinical Features of Neurotransmitter Disorders Neonatal progressive encephalopathyNeonatal or infantile medically-refractory epilepsyInfantile myoclonic epilepsyExtrapyramidal movement disorder (parkinsonism, dystonia, ataxia)Ptosis, miosis, oculogyric crisisAbnormal autonomic function: hypersalivation, disturbed intestinal motility, disturbances of temperature regulationTreated with carbidopa/levodopa, 5HTP, SSRIs, leucovorin"
  },
  {
    "section": "neurogenetics-and-neurometabolics",
    "sectionName": "Neurogenetics and Neurometabolics",
    "heading": "Leukodystrophies / Leukoencephalopathies",
    "id": "leukodystrophies-leukoencephalopathies",
    "text": "Vanishing White Matter Disease: AR neurological disease. Mutations in any of the 5 genes encoding subunits of the translation initiation factor EIF-2B (EIF2B1, EIF2B2, EIF2B3, EIF2B4, or EIF2B5). Symptoms include cerebellar ataxia, spasticity, optic atrophy, epilepsy, loss of motor functions, irritability, vomiting, coma. Adrenoleukodystrophy (X-linked): peroxisomal disorder so elevated VLCFA. Usually presets as behavioral, visual, auditory problems in boys & has posterior 🡪  anterior progression with enhancing front on MRI. ‘Lorenzo’s oil’ corrects serum VLCFAs but doesn’t help already sympt"
  },
  {
    "section": "neurogenetics-and-neurometabolics",
    "sectionName": "Neurogenetics and Neurometabolics",
    "heading": "Workup of Leukodystrophies/Leukoencephalopathies",
    "id": "workup-of-leukodystrophies-leukoencephalopathies",
    "text": "Blood CSF Cellular elementsLymphocyte granulation: MLD-MSD,  Anemias: Mito d/o  Cellular elementsElevated in AGSVLCFAElevated in X-ALD  Total proteinElevated in Krabbe, MLDLysosomal Enzyme activitiesArylsulfatase A low in MLDGalacto-cerebrosidase low in KrabbeFucosidase low in Fucsidosis  AsialotransferrinsElevated in VWMDLactateElevated in LBSL  5-MTHFLow in Folate rec defectAsialotransferrinsElevated in CDG (d/o glycosylation)  LactateElevated in LBSLCholestanolElevated in CTX  InterferonAGSDNA preparationFrequently useful  GlyineElevated in GLYUrine Biopsies SulfatidesElevated in MLD  Skin"
  },
  {
    "section": "neurogenetics-and-neurometabolics",
    "sectionName": "Neurogenetics and Neurometabolics",
    "heading": "Childhood disease of the Basal Ganglia",
    "id": "childhood-disease-of-the-basal-ganglia",
    "text": "Childhood disease of the Basal Ganglia AcuteChronicHypoxia   HypoglycemiaCarbon Monoxide poisoningHUSOsmotic myelinolysisEncephalitis Inborn errors of metabolism·       Leigh Disease   ·       MELAS   ·       Glutaric acidemia type II     ·       Methylmalonic acidemia·       Maple syrup urine disease·       Wilsons disease·       Degenerative Diseaseso   Juvenile Huntington disease·       Other diseaseso   NF1o   Sequelae of acute insultso   Basal Ganglia calcifications·       Dysmyelinating diseaseso   Canavan Diseaseo   Metachromatic leukodystrophy   Conditions associated with Basal Ganglia"
  },
  {
    "section": "other-topics",
    "sectionName": "Other Topics",
    "heading": "Dermatomes/Myotomes",
    "id": "dermatomes-myotomes-2",
    "text": "From <https://childrenscolorado-my.sharepoint.com/personal/adam_finney_childrenscolorado_org/Documents/ChildNeurologyResidentHandbook_FINAL.docx>"
  },
  {
    "section": "other-topics",
    "sectionName": "Other Topics",
    "heading": "Spinal Levels in Spina Bifida",
    "id": "spinal-levels-in-spina-bifida-2",
    "text": "From <https://childrenscolorado-my.sharepoint.com/personal/adam_finney_childrenscolorado_org/Documents/ChildNeurologyResidentHandbook_FINAL.docx>"
  },
  {
    "section": "other-topics",
    "sectionName": "Other Topics",
    "heading": "Spinal Reflexes",
    "id": "spinal-reflexes-2",
    "text": "Spinal Cord Reflexes    JawCN 5CremastericL1,2BicepsC5-6KneeL3-4BrachioradialisC5-6Extensor HallucisL5TricepsC7AnkleS1FingerC8PlantarS1Abdominal—upperT9-10BulbocavernousS2-4     From <https://childrenscolorado-my.sharepoint.com/personal/adam_finney_childrenscolorado_org/Documents/ChildNeurologyResidentHandbook_FINAL.docx>"
  },
  {
    "section": "other-topics",
    "sectionName": "Other Topics",
    "heading": "Concussion",
    "id": "concussion",
    "text": "Concussion Management Concussion is variably defined by different medical organizations but includes the following:Transfer of mechanical energy either by a direct blow or sudden acceleration/deceleration to the head resulting inAlteration of consciousness, post-traumatic amnesia < 24 hours, traumatic seizure, transient focal neurologic deficit or a GCS of 13-14.  Diagnosis of acute concussion involves assessment of: Mental status at time of injury or medical evaluation as noted aboveSymptoms typical of concussion in the following domains: somatic (e.g. headache, nausea), cognitive (e.g. inatt"
  },
  {
    "section": "other-topics",
    "sectionName": "Other Topics",
    "heading": "Radiation Exposure",
    "id": "radiation-exposure-2",
    "text": "Radiation dose is measured by millisievers (mSv). Naturally occurring “background” radiation exposure is estimated to be 3 mSv per year.  At higher elevations (e.g. Denver, ~5,280 ft), there is about 1.5 mSv more per year than living at sea level. Round trip flight from coast to coast is 0.03 mSv. CT Head has 2 mSv which equates to 8 months of exposure to naturally occurring radiation. Additional lifetime risk of fatal cancer from examination is thought to be very low (1 in 100,000 to1 in 10,000)CT Head with and without is 4 mSv. Additional risk is low.   From <https://childrenscolorado-my.sharepoint.com/personal/adam_finney_c"
  },
  {
    "section": "pediatric-normal-values",
    "sectionName": "Pediatric Normal Values",
    "heading": "Head Circumference Charts",
    "id": "head-circumference-charts-2",
    "text": "From Cincinnati Children’s Hospital.   General rule of thumb: birth – 35cm, 1 yr – 45cm, adult – 55cm          OR Birth 35cm    3 mo 40 cm    9 mo 45 cm    3 yr 50 cm     9 yr 55 cm Boys  Girls                From <https://childrenscolorado-my.sharepoint.com/personal/adam_finney_childrenscolorado_org/Documents/ChildNeurologyResidentHandbook_FINAL.docx>"
  },
  {
    "section": "pediatric-normal-values",
    "sectionName": "Pediatric Normal Values",
    "heading": "Pediatric Blood Pressure Charts",
    "id": "pediatric-blood-pressure-charts-2",
    "text": "From <https://childrenscolorado-my.sharepoint.com/personal/adam_finney_childrenscolorado_org/Documents/ChildNeurologyResidentHandbook_FINAL.docx>"
  },
  {
    "section": "stroke",
    "sectionName": "Stroke",
    "heading": "Stroke Alerts",
    "id": "stroke-alerts",
    "text": "STROKE ALERT Inclusion CriteriaAge >1 monthFocal neurologic deficits with duration <24h (unilateral weakness or numbness, aphasia, ataxia, visual field cut)   Appropriate Workup/Procedures  EPIC Orderset ParametersNormothermia: treat >38.3°C with acetaminophenNormotensive: Notify neurology if SBP <50th or >95th percentile for ageNormal O2: >90% SpO2Normovolemia: use normal saline (avoid IVF until intracranial mass ruled out)Establish IV access and make patient NPOHOB Flat. If signs of increased ICP, elevate bed to 30 degrees and order STAT Head CTStudiesEKG, Chest X-rayLabsCBC, CMP, DIC Panel,"
  },
  {
    "section": "stroke",
    "sectionName": "Stroke",
    "heading": "TPA Form",
    "id": "tpa-form",
    "text": "INDICATIONS TO consider TPA (All need to be YES):YesNoIs patient 2 years or older?  Is clinical presentation consistent with an ischemic stroke corresponding to an arterial vascular territory?  Does the patient have a significant neurological deficit as defined as PedsNIHSS >6, or a life altering deficit?  Can IV tPA be given within 4.5 hours of last known normal?  Is there radiographically confirmed ischemic stroke by either:a)     MRI confirmation with restricted diffusion in vascular territory, with or without occlusion of intracranial artery?CT head that is normal or early area of hypodens"
  },
  {
    "section": "stroke",
    "sectionName": "Stroke",
    "heading": "Intra-arterial Therapy Checklist",
    "id": "intra-arterial-therapy-checklist",
    "text": "Considerations for Pediatric Patients <6 hours from symptom onset  Patient meets criteria for possible thrombectomy if yes to all the following: YESNO   Patient > 3 years of age?+  Able to perform groin puncture prior to last known normal of 6 hours?*   Little to no pre-stroke disability?*  NIHSS > 6?*  Occlusion of ICA or M1 on MRA?*  MRI ASPECTS Score > 6* or < 1/3rd MCA?+Does patient meet criteria for IV tPA? If yes, may consider IV tPA first. Treatment does not influence thrombectomy decision*   If all of the above criteria are met, the child meets all of the current AHA Acute Ischemic Str"
  },
  {
    "section": "stroke",
    "sectionName": "Stroke",
    "heading": "Early Decompressive Surgery in Malignant Infarction",
    "id": "early-decompressive-surgery-in-malignant-infarction",
    "text": "Large Infarct Volume (e.g. greater than 50% of MCA) territory [as determined by neuroradiology, neurosurgery and neurology] on presenting CT or MRI.Age > 1 year.Timepoint < 48 hours from last known normal. If patient meets these criteria, the patient should be admitted to the PICU (or CICU).  The neurosurgical team should decide upon either: 1) early decompressive surgery in first 24 hours, or 2) close monitoring.  Close monitoring should include: Scheduled fast-sequence MRI (or CT scans if MRI unfeasible or unavailable) x 48 hours as permitted by clinical condition (Suggested: Q8-12 hours for"
  },
  {
    "section": "stroke",
    "sectionName": "Stroke",
    "heading": "Pediatric NIHSS",
    "id": "pediatric-nihss",
    "text": "(Also available on MDCalc)"
  },
  {
    "section": "stroke",
    "sectionName": "Stroke",
    "heading": "Stroke mimics",
    "id": "stroke-mimics",
    "text": "Seizure with Todd’s paralysis, hemiplegic migraine, Bell’s palsy, Alternating hemiplegia of childhood, Brain tumor, CNS infection (meningitis/encephalitis/abscess), posterior reversible encephalopathy syndrome (PRES), demyelinating disease (MS, ADEM, transverse myelitis, NMO, anti-MOG, ADIP), SOD, CMTX, Idiopathic intracranial hypertension, acute cerebellar ataxia   Ischemic Stroke DDx & Associated Workup  Specific diagnosesTesting to ConsiderCardiac (cardioembolic and hypoperfusion)Congenital heart disease, endocarditis Echo w/bubble, EKG Arteriopathy, HemoglobinopathyFocal cerebral arteriopa"
  },
  {
    "section": "stroke",
    "sectionName": "Stroke",
    "heading": "Moya Moya Differential and Work-up Considerations",
    "id": "moya-moya-differential-and-work-up-considerations",
    "text": "Differential: Alagille Syndrome, Down Syndrome, microcephalic osteodysplastic primordial dwarfism, neurofibromatosis type 1, PHACE syndrome, Robinow syndrome, Seckel syndrome, sickle cell disease, radiation sequel, tuberous sclerosis, Marfans Genetic considerations: RNF213, ACTA2, R179, BRCC3/MTCPI, GUCYIA3, SAMHD1 Note: There is a special protocol for anesthesia for Moya Moya kids. If not present Note: For patients with Moya Moya, TPA is contraindicated, may be thrombectom y candidate"
  },
  {
    "section": "stroke",
    "sectionName": "Stroke",
    "heading": "Intraventricular Hemorrhage: Grading",
    "id": "intraventricular-hemorrhage-grading",
    "text": "Image Source: https://www.childrensmn.org"
  },
  {
    "section": "stroke",
    "sectionName": "Stroke",
    "heading": "Neonatal Stroke",
    "id": "neonatal-stroke",
    "text": "AgePerinatal IVH/periventricular venous infarctPerinatal CSVT w/wo StrokePerinatal arterial ischemic strokeNICUNo thrombophilia testing unless family history is positive for early DVT, PE, MI or AIS (usually age <50y), unusual in extent/severity, propagating infarct or presence of extra-cranial thrombosisRefer to Early Intervention   Consider COL4A1 genetic testing if congenital cataracts and/or family history of cerebral palsy, hemorrhagic stroke, early unexplained deathInitiate enoxaparinECHO only if multifocal stroke and/or abnormal cardiac exam2-4 weeksConsider maternal anti-phospholipid a"
  },
  {
    "section": "stroke",
    "sectionName": "Stroke",
    "heading": "Childhood CSVT",
    "id": "childhood-csvt",
    "text": "PresentationConsults: Neuro, Hematology +/- NSGY if substantial bleeding, large clot or possibility for endovascular txAnticoagulation per hematology: start w/UFH if high bleed risk, enoxaparin if average bleed risk, with transition to warfarin if preferred. May need multi-disciplinary approach if complex med hxDirect oral anticoagulant (i.e. rivaroxaban, apixaban) can be considered (if not obese, not triple +APL Ab)Thombophilia testing w/APLA workup (dRVVT, hexagonal PTT, anticardiolipin, anti-beta-2-glycoprotein) + hematology recsIf mastoiditis/severe infection, can do just APLA workup. Othe"
  },
  {
    "section": "neurocritical-care",
    "sectionName": "Neurocritical Care",
    "heading": "Brain Death Policy",
    "id": "brain-death-policy",
    "text": "Brain Death Policy Guidelines GENERAL INFORMATION Brain death is the total & irreversible cessation of ALL brain function, including that of the cortex and brainstem. The determination of brain death is the legal responsibility of the attending physician. The diagnosis of brain death is a clinical diagnosis based on the absence of neurologic function with a known irreversible cause of coma. Brain death testing should not be initiated immediately post cardiopulmonary arrest or acu"
  },
  {
    "section": "neurocritical-care",
    "sectionName": "Neurocritical Care",
    "heading": "Glasgow Coma Scale",
    "id": "glasgow-coma-scale",
    "text": "Glasgow Coma Scale Modified Coma Scale for Infants ActivityBestResponseActivityBestResponseEYE OPENING   Spontaneous4Spontaneous4To speech3To speech3To pain2To pain2None1None1VERBAL   Oriented5Coos, babbles5Confused4Irritable4Inappropriate words3Cries to pain3Nonspecific sounds2Moans to pain2None1None1MOTOR   Follows commands6Normal spontaneous mov’ts6Localizes pain5Withdraws to touch5Withdraws to pain4Withdraws to pain4Abnormal flexion3Abnormal flexion3Abnormal extension2Abnormal extension2None1None1"
  },
  {
    "section": "neurocritical-care",
    "sectionName": "Neurocritical Care",
    "heading": "ICP management",
    "id": "icp-management",
    "text": "Elevated ICP: Typically defined as ICP greater than 20-25 for 10 minutesGoal ICP is typically less than 20Clinical signs often include: headache, vomiting, vision changes, change in mental status or depressed mental status, pupillary changes, and cushing's triad (hypertension, bradycardia, irregular breathing) as a late sign and suggest impending herniationSee Pupillometry for noninvasive ICP monitoring   Treatment: For TBI, refer to TBI pathway (in Clinical Pathway chapter)Early involvement of NSGY (NSGY typical aids in ICP management)Optimize sedation and pain co"
  },
  {
    "section": "neurocritical-care",
    "sectionName": "Neurocritical Care",
    "heading": "Pupillometry",
    "id": "pupillometry",
    "text": "Pupillometer (NPI) is a non-invasive device that uses an infrared camera that integrates a calibrated light stimulation of fixed intensity and duration allowing for a rapid and precise measure (0.05 mm limit) of the pupil size and of a series of dynamic pupillary variables.NPI ranges from 0-5 (0.1 decimal increments)NPI represents a proprietary scalar index (pupil size, percentage pupillary constriction, latency, constriction velocity, and dilation velocity).Pathological NPI values are defined as less than 3Lower NPI values suggest higher ICPChanges in NPI trends can represent ICP changes and"
  },
  {
    "section": "neurocritical-care",
    "sectionName": "Neurocritical Care",
    "heading": "Hypoxic-Ischemic Encephalopathy (HIE)",
    "id": "hypoxic-ischemic-encephalopathy-hie",
    "text": "Eligibility Criteria for Therapeutic Hypothermia (cooling): 1. Gestational Age ≥ 35 weeks AND 2. Infant less than 6 hours of age (The decision to start hypothermia after 6 hours will be at the discretion of the neonatology attending) AND 3. Clinical signs consistent with encephalopathy AND 4. Evidence of intrapartum hypoxia including one of the following: Prolonged resuscitation: continued need for positive pressure ventilation; required at birth and continued for greater than or equal to 10 minutes.Apgar score at 10 minutes ≤ to 5.Blood gas [arterial cord gas, venous cord gas, or postnatal (w"
  },
  {
    "section": "neurocritical-care",
    "sectionName": "Neurocritical Care",
    "heading": "Post-Arrest",
    "id": "post-arrest",
    "text": "-Consider early CTH if asymmetric exam, etiology unclear, or deemed useful for early prognostication -Consider CTA neck in cases of hanging -cEEG for at least 24 hours (and then as clinically indicated) -myoclonic status is a poor prognostic feature but we do typically treat with loads, +/- midazolam drip.  We typically avoid pentobarbital drip for purposes of myoclonic status epilepticus. -Neuroprotective measures -Avoid hypotension  -Normoxia (SpO2 92%-95% or PaO2 60-300 mmHg)  -Normocarbia (pCO2 35-45 mmHg)  -Normonatremia (Na 135-145 mmol/L, unless ICP concerns)  -Normothermia (avoid fever"
  },
  {
    "section": "movement-disorders",
    "sectionName": "Movement Disorders",
    "heading": "Examination",
    "id": "examination",
    "text": "Exam ManeuverExamples of AbnormalitiesGeneralQuiet sitting w/ & w/o suppressionAbnormal movements present at restTitubation (bobbing of head and/or trunk)Cranial NervesFixation of GazeNystagmusImpairment with maintaining gazeSquare Wave Jerks Smooth PursuitBreakdown with jerky saccades Large saccadesOver- or undershootingBlink to initiate saccade Speech-Coordination of sounds-Quality of sound-Pronunciation-Modulation of pitch-Inflection-Holding ‘aah’ and ‘eeh’ soundsDysrhythmia / Clumsy and AtaxicDysarthric for labial, lingual &/or guttural soundsScanning speech / abnormal prosodyTremorSoft, s"
  },
  {
    "section": "movement-disorders",
    "sectionName": "Movement Disorders",
    "heading": "Tremor",
    "id": "tremor",
    "text": "Postural > Resting     Regular+ Family historyà Electrolytes and TFTsNo family history à Above and MRI brainIrregular and jerkingConsider myoclonic or dystonic tremor and corresponding syndromes   Resting > Postural Conversion or Parkinsonian   Etiology of action tremor- both columns are causes Familial essential tremorWeaknessGenetic such as      Myoclonus-dystonia syndrome      Dystonias / CMT     chromosomal abnormalitiesPeripheral neuropathyCerebellar tremorPsychogenic Etiology of action tremor Meds/drugs/tox albuterol, amiodarone, VPA amphetamines, arsenic, caffeine, cocaine, cyanide, cyc"
  },
  {
    "section": "movement-disorders",
    "sectionName": "Movement Disorders",
    "heading": "Ataxias",
    "id": "ataxias",
    "text": "ACUTE-ONSET ATAXIA: in previously healthy childrenEtiologyTypical PresentationDrug or Med Ingestion1-4 yo may have nystagmus & encephalopathyCerebellitisAcute severe ataxia, MS change, concern for cerebellar swelling; can see URI antecedentBasilar MigraineOther accompanying migrainous featuresBenign Paroxysmal VertigoOther accompanying migrainous featuresBrainstem EncephalitisCN dysfunction, encephalopathy, szs, vomitNeuroblastoma (paraneoplastic)Encephalopathy, irritability, opsoclonus, distal myoclonusConversion ReactionInconsistent exam, late 1st early 2nd decade of lifeTrauma: Hematoma, Po"
  },
  {
    "section": "movement-disorders",
    "sectionName": "Movement Disorders",
    "heading": "Work-up for Cerebellar Dysfunction",
    "id": "work-up-for-cerebellar-dysfunction",
    "text": "Acute: CT scan, Utox, CMPConsider MRI/MRA if concern for stroke or vascular lesionConsider LP if encephalopathic and neg scan, or suspect infectious or inflammatory etiologyMIBG scan, urine HVA and VMA, and chest/abd/pelvis CT +/- contrast if suspect paraneoplastic (such as opsoclonus myoclonus ataxia secondary to neuroblastoma), LP and serum paraneoplastic panelsRecurrentMRI, MRA, MRSConsider LP for CSF glucose if MRI normalAdditional genetic and metabolic testing based on results of above and clinical featuresChronicMRI +/- MRA, MRSVitamin E levelConsider LP pending MRI result, to check gluc"
  },
  {
    "section": "movement-disorders",
    "sectionName": "Movement Disorders",
    "heading": "Dystonia Treatment",
    "id": "dystonia-treatment",
    "text": "Allen M, Lin J-P, Lynch T, King M. Status dystonicus: a practice guide. Developmental & Child Neurology. 2013 Dec; Vol 56, Issue 2. P. 105-112, Fig 1. https://doi.org/10.1111/dmcn.12339     Oral Medications for the Treatment of Dystonia For outpatient initiation: start low and titrate to the lowest effective dose for symptom control with tolerable side effects. To minimize side effects, start with divided dose given daily and titrate to BID-QID [depending on t1/2].    Dosing information below is based on available literature in pediatric patients for dystonia/spasticity. If no dosing informati"
  },
  {
    "section": "movement-disorders",
    "sectionName": "Movement Disorders",
    "heading": "Chorea",
    "id": "chorea",
    "text": "Definition - Unsustained rapid irregular non-patterned asymmetric movements that are purposeless. Most difficult to distinguish from cortical myoclonus.  Typically, no urge and not suppressible. On examination, ask patient to sit completely at rest, chorea is typically present distally in fingers and toes and increases with purposeful movement of involved body part.    DDX Acute/Subacute Chorea AutoimmunePoststreptococcal/Sydenham choreaSLEAntiphospholipid antibody Henoch-Schonlein PurpuraInfection/ encephalitisMycoplasmaLymeHSVTBVascular/Hypoxic ischemicStroke/moya-moyaVasculitis“Post pump ch"
  },
  {
    "section": "movement-disorders",
    "sectionName": "Movement Disorders",
    "heading": "Tics",
    "id": "tics",
    "text": "resources: https://tourette.org DSM – IV TR Diagnostic criteria for tic disorders    Transient Tic DisorderChronic Tic DisorderTourette’s SyndromeOnset before 18 years, typically age 4-6Onset before 18 years, typically age 4-6Onset before 18 years, typically age 4-6Single or multiple motor and/or vocal ticsMultiple motor or vocal ticsMultiple motor and vocal tics, although need not be simultaneously present, for >12 monthsTics occur many times a day, nearly every day for at least 4 weeks but not more than 12 consecutive monthsTics occur many times a day, nearly every day for greater than one y"
  },
  {
    "section": "development",
    "sectionName": "Development",
    "heading": "Developmental Milestones",
    "id": "developmental-milestones",
    "text": "https://pedsinreview.aappublications.org/content/37/1/25.long  AgeLanguageGross motorFine motorSocialBirthUndifferentiated but strong cryMomentary head control when held sitting Flexion Quiets readily1 moVocalizes/Throaty NoiseStartles to soundTurns head supineChin up proneHands fist near faceRegards faceKnows parent voiceCries when distressed2 moCoos (ohh, ah)Alerts to soundChest up when proneHead bobs when sittingHands not fists 50%Holds rattle if placedHands togetherSocial smileOpens mouth at sight of breast/bottle4 moLaughs/squealsOrients head and soothes to voiceRolls front to backSits wi"
  },
  {
    "section": "development",
    "sectionName": "Development",
    "heading": "Developmental Red Flags",
    "id": "developmental-red-flags",
    "text": "Time PeriodLanguage/CognitiveMotorSocial-EmotionalNeonateNo respond to loud sounds.Muscle tone too low to feed.Caregiver shows indifference/disinterest2 moDoes not alert to voice.Cannot raise head when prone.Lack of looking at faces/lack of fixation.4 moNo cooing or gurgling sounds.Unable to bring hands to midline.Lack of smiling.6 moLack of turning toward voices.Does not pass object from one hand to another.No smiling, laughing, or expression.9 moLack of babbling with consonants.Inability to sit. Lack of rolling.Absence of back-and-forth smiles and vocalizations in “conversation.”12 moNo resp"
  },
  {
    "section": "development",
    "sectionName": "Development",
    "heading": "Developmental Reflexes",
    "id": "developmental-reflexes",
    "text": "Primitive ReflexesDescriptionAppearsDisappearsBlink to lightInfant will blink or close eyes forcefully when a bright light is shone~26 weeks gestationPersistsPupillary ResponsePupils will constrict directly and consensually with bright light~31-34 weeks gestationPersistsMoro/startleA sudden change in position or loud noise causes infant’s arms/fingers to extend and then come togetherIn utero at 28 weeks’ gestation3-6 months of ageStepping/placingBaby appears to take steps or dance when held upright32 weeks gestationPersists as voluntary standingPositive supportingInfant is suspended with suppo"
  },
  {
    "section": "development",
    "sectionName": "Development",
    "heading": "Intellectual disability vs. Learning Disability",
    "id": "intellectual-disability-vs-learning-disability",
    "text": "Intellectual disability implies global developmental impairment. Language, visual motor skills, integration and problems-solving skills, and functional living skills are all impaired (IQ <70; 2.2 % of population). Both a functional disability and low IQ must be demonstrated to give this dx.Learning disability is defined by normal overall development but difficulties in acquiring or performing specific skills (e.g. reading or arithmetic). Specific processing difficulties are identifiable, difficulties are not associated with limited exposure, language difference, emotional issues or sensory def"
  },
  {
    "section": "development",
    "sectionName": "Development",
    "heading": "IEP (Individual Education Plan) v 504",
    "id": "iep-individual-education-plan-v-504",
    "text": "IEP IDEA requires all schools to provide a free and appropriate education to all students, regardless of disabilityAn evaluation must be completed to determine if child qualifies for services (for ex, special education, speech therapy, psychological services)To qualify, must have a disability AND it must be educationally handicapping (can’t just have ADHD and automatically get an IEP) An Individual Education Plan (IEP) is developed documenting remedial services to be provided and annual goals to be achievedIncludes many specific procedures and safeguards that must be followed in developing and"
  },
  {
    "section": "development",
    "sectionName": "Development",
    "heading": "Memory deficits",
    "id": "memory-deficits",
    "text": "Complaints of “poor memory” are ubiquitousVery few children have specific and isolated memory deficitsMost “memory” problems turn out to be:Decreased overall abilityLearning disabilityInattention / ADHDPoor behavioral control Ask parents to tell you what they are observing, rather than giving it a name (“memory problems”).  “Tell me what you notice XXX doing”She remembers how to read a word at the top of the page, but doesn’t remember what word it is at the bottom of the page (NOT a memory problem; often a complaint in reading disabled children)He doesn’t remember to bring home his homework or"
  },
  {
    "section": "development",
    "sectionName": "Development",
    "heading": "Evaluation of Global Developmental Delay",
    "id": "evaluation-of-global-developmental-delay",
    "text": "Definition of GDD: there must be significant impairment (>2 SD from norm) in at least 2 of the following areas: Motor (gross or fine), speech and language, cognition, personal-social, activities of daily living. If ≥2 areas are not involved, or the impairment is not significant, the GDD/ID diagnosis is not applicable and evaluation should not be undertaken. There are different recommended evaluations for isolated language disorders and autistic spectrum disorders.      Table demonstrating recommendations for first-line investigations for GDD from 4 guidelines & proposed recommendations (Mithya"
  },
  {
    "section": "sleep",
    "sectionName": "Sleep",
    "heading": "Sleep Requirements by Age",
    "id": "sleep-requirements-by-age",
    "text": "Recommended Amount of Sleep by Age Newborn 0–3 months 14–17 hours  Infant      4–12 months 12–16 hours per 24 hours (including naps) Toddler   1–2 years 11–14 hours per 24 hours (including naps) Preschool 3–5 years 10–13 hours per 24 hours (including naps) School Age 6–12 years 9–12 hours per 24 hours Teen         13–18 years 8–10 hours per 24 hours Adult        18–60 years 7 or more hours per night                  61–64 years 7–9 hours                  65 years and older 7–8 hours"
  },
  {
    "section": "sleep",
    "sectionName": "Sleep",
    "heading": "Insomnia",
    "id": "insomnia",
    "text": "Diagnostic Criteria for Insomnia (must have one from A - F)   Criteria A Difficulty initiating sleepDifficulty maintaining sleepWaking up earlier than desiredResistance to going to bed on appropriate schedule Difficulty sleeping without parent or caregiver intervention Criteria B Fatigue/malaiseAttention, concentration or memory impairmentImpaired social, family, occupational, or academic performanceMood disturbance/irritabilityDaytime sleepinessBehavioral problems Proneness for errors/accidents Criteria C The reported sleep/wake complaints cannot be explained purely by inadequate opportunity"
  },
  {
    "section": "sleep",
    "sectionName": "Sleep",
    "heading": "Insomnia Treatment",
    "id": "insomnia-treatment",
    "text": "Behavioral strategies should always be first line! Make sure clocks are not visible during the night, as watching the time can increase anxiety and cause the brain to wake up more to think about the time. Spend most of the time you are in bed asleep rather than awake.  Retraining \"Sleep Associations\" Stimulus Control: If you are unable to fall asleep [or fall back to sleep] after approximately 20-30 minutes (use your best estimate, do not check the time), you should get out of bed and engage in a relaxing activity (reading, meditation - no screens or bright light) for approximately 20 minutes"
  },
  {
    "section": "sleep",
    "sectionName": "Sleep",
    "heading": "SLEEP ONSET INSOMNIA",
    "id": "sleep-onset-insomnia",
    "text": "Melatonin INDICATION: sleep onset insomnia, circadian phase delay DOSING: 0.5 - 5 milligrams 30 minutes prior to bedtime (soporific)    Clonidine (comorbid ADHD) INDICATION: sleep onset insomnia, particularly useful when there are severe sleep onset problems in pediatric RLS and PLMD. Clonidine has a relatively short duration of effect, it may not be effective for problems with sleep maintenance. DOSING: 6 - 12 years old: initial dose is 0.05 mg, one-half hour prior to bedtime. The dose can be sequentially increased every three to seven days in 0.05 mg/day increments, until sleep onset is impr"
  },
  {
    "section": "sleep",
    "sectionName": "Sleep",
    "heading": "SLEEP MAINTENANCE INSOMNIA",
    "id": "sleep-maintenance-insomnia",
    "text": "Trazodone (comorbid anxiety) INDICATION: sleep onset and/or maintenance insomnia DOSING: 25 mg - 150 mg  Initial – 1-2 mg/kg/dose, Max first dose 25 mg for 18 mo - 3 yo and 50 mg >3 yo Increase by 12.5 mg/dose Q1-2 weeks Maintenance – 100 mg for 18 months to 3 yo, 150 mg/ 3 - 5yo, 200 mg >5 yo MOA: Inhibits uptake of serotonin, histamine and alpha-1-adrenergic receptor antagonist.  FYI, can cause prolonged QT. Onset: 30 - 120 minutes, delayed with food (up to 2.5 hours), Half-Life: 7 – 15 hours SIDE EFFECTS: Blurred vision, Dizziness 20-28%, Dry Mouth 15 - 34%, Headache 10 - 33%, Nausea/Vomiti"
  },
  {
    "section": "sleep",
    "sectionName": "Sleep",
    "heading": "NREM Parasomnias",
    "id": "nrem-parasomnias",
    "text": "Parasomnias can involve physical and verbal activity of varying complexity. Typically, the sleeper returns to sleep. Amnesia to the event is part of the diagnostic criteria for NREM parasomnias, with the behavior being observed by others. NREM parasomnias include sleep terrors, sleep walking and confusional arousals and occur during NREM sleep.   External (e.g., noise, temperature change) or internal (e.g., apnea, periodic limb movement) events may cause an arousal or partial awakening, usually from stage III sleep, which occurs in the first 90 minutes of the sleep period. Arousal or partial a"
  },
  {
    "section": "sleep",
    "sectionName": "Sleep",
    "heading": "Differentiating Nocturnal Frontal Lobe Epilepsy and Parasomnias",
    "id": "differentiating-nocturnal-frontal-lobe-epilepsy-and-parasomn",
    "text": "Management of Parasomnias  Labs: Check an iron level (serum ferritin). Low (or low-ish) iron levels may trigger restlessness, restless legs, periodic limb movements, etc that disrupt deep sleep. Sleep fragmentation can trigger parasomnias. If there are symptoms of sleep apnea, a sleep study may be indicatedDo not try to awaken, simply guide back to bed. Keep the room dark, quiet, calm, etc. To keep safe, consider alarms on the doors so that you hear if he/she is getting out of the room. Consider securing windows, with nails if needed, to prevent falling out of the window. To not \"barricade\" st"
  },
  {
    "section": "sleep",
    "sectionName": "Sleep",
    "heading": "CENTRAL HYPERSOMNIAS",
    "id": "central-hypersomnias-2",
    "text": "Idiopathic HypersomniaHypersomnia due to a medical condition Narcolepsy with Cataplexy Narcolepsy without Cataplexy Klein-Levin Syndrome    Hypersomnia is characterized by excessive daytime sleepiness. Patients can present with a history of frequently falling asleep in school, car rides and/or other situations and/or taking frequent naps past the age of 4. Hypersomnia is a rare cause for daytime sleepiness. Common causes of daytime sleepiness includes insufficient sleep for age, inconsistent sleep/wake schedule (eg social jet lag), inadequate sleep hygiene and obstructive sleep apnea.    Evalu"
  },
  {
    "section": "psychiatry",
    "sectionName": "Psychiatry",
    "heading": "Functional Neurological Symptom Disorder",
    "id": "functional-neurological-symptom-disorder",
    "text": "It is an unconscious bodily response to stress, similar to diarrhea, stomachache, or migraine. Patients are not consciously producing the movements, and should not be blamed or accused of “making it up”.   Clinical presentation and physical findings: Possible signs or symptoms: Nonepileptic seizuresMovement disorder (tremor, chorea, etc) Weakness, balance or walking problemsVision changesSpeech changesSymptoms persist whether the patient is observed or unobserved, though are typically worse when the patient is attentive to them.Physical exam findings that are consistent with functional neurolo"
  },
  {
    "section": "psychiatry",
    "sectionName": "Psychiatry",
    "heading": "Neurologic Side Effects of Psychiatric Medications",
    "id": "neurologic-side-effects-of-psychiatric-medications",
    "text": "Extrapyramidal Side EffectsMedication induced movement disorder caused by dopamine blocking agentsTime course: usually occurs shortly after a medication is given.  Can occur with first dose or after receiving multiple doses.  SymptomsAkathisia, rigidity, bradykinesia, tremor, acute dystonic reactionCan resemble ParkinsonismMedications that can cause EPS:First generation anti-psychotic agents: Higher risk: haloperidol, fluphenazine, perphenazine, Lower risk: chlorpromazine, thioridazineSecond generation anti-psychotic agents: Lower risk than first generation antipsychoticsHigh risk: risperidone"
  },
  {
    "section": "psychiatry",
    "sectionName": "Psychiatry",
    "heading": "New Onset Hallucinations workup",
    "id": "new-onset-hallucinations-workup",
    "text": "Hallucinations - involuntary experience of erroneous percepts in the absence of identifiable external stimuli Pediatric organic conditions which may present with hallucinations or related perceptual phenomena – with or without reduced levels of consciousness (Freudenreich 2009; Algon 2012) Neurological disordersMigraines with aura (e.g. Alice in Wonderland Syndrome); sleep disorders (e.g. narcolepsy), epilepsy (i.e. complex partial seizures, temporal lobe epilepsy), malignancies, brain space-occupying lesions, head injury, demyelinating diseases (multiple sclerosis), basal ganglia disease (Wil"
  },
  {
    "section": "psychiatry",
    "sectionName": "Psychiatry",
    "heading": "Catatonia",
    "id": "catatonia",
    "text": "Definition: behavioral syndrome marked by an inability to move normally, which can occur in the context of many underlying psychiatric and general medical disorders    Observed Signs of Catatonia: FeatureDescription and examplesImmobilityHypokinetic or akinetic behavior that is not influenced by external stimuli.StuporDecreased alertness, hypoactivity, and diminished responses to voice and painful stimuli.ExcitementImpulsive, frantic, and stereotypic behavior that may include sudden outbursts of talking, singing, dancing, and tearing of clothes. Patients may be irritable and damage objects or"
  },
  {
    "section": "psychiatry",
    "sectionName": "Psychiatry",
    "heading": "ADHD Medications",
    "id": "adhd-medications",
    "text": "https://chadd.org/wp-content/uploads/2018/05/Medication-Chart-October-2017.pdf"
  },
  {
    "section": "neuro-on-call",
    "sectionName": "Neuro On-Call Quick References",
    "heading": "Seizure & Status Epilepticus",
    "id": "status-epilepticus",
    "text": "[image: Status Epilepticus Pathway] [image: Neonatal Seizures Reference] [pdf: YES Epilepsy Pocket Card] [pdf: Seizure Protocol Reference]"
  },
  {
    "section": "neuro-on-call",
    "sectionName": "Neuro On-Call Quick References",
    "heading": "Seizure Medications & Dosing",
    "id": "seizure-medications",
    "text": "Diastat/Diazepam Dosing (Weight Based) \n\n\nGeneric [Trade]Abbrev (Yr)FDA‑Labeled IndicationFormulation (§ = generic)Cost†Mechanism of ActionAdult Dose (mg/day) initial → maxChild Dose initial ; maint mg/kg/dayTypical Dose increases Time ➜ Steady‑State / PKT½ (h), % bound [ther. level μg/mL]Key Drug InteractionsCommon / Serious Adverse EffectsNotes & PearlsMonitoring / “To Do”\nAcetazolamide [Diamox]AZM (1952)Adjunct for various seizure types (off-label)Tab, IV$Carbonic anhydrase inhibitor250 → 1000 (BID-TID)5 ; 10–15↑ 250 mg q1–2wk (ad); ↑ 5 mg/kg/d q1–2wk (p)2–3 d; T½ 6–9 h, 90 %May alter excre"
  },
  {
    "section": "neuro-on-call",
    "sectionName": "Neuro On-Call Quick References",
    "heading": "Stroke",
    "id": "stroke",
    "text": "[pdf: AHA/ASA: Management of Stroke in Neonates & Children]"
  },
  {
    "section": "neuro-on-call",
    "sectionName": "Neuro On-Call Quick References",
    "heading": "Clinical Reference Images",
    "id": "clinical-reference-images",
    "text": "[image: IMG_7641.jpeg] [image: IMG_7642 (1).png] [image: IMG_7643.jpeg] [image: IMG_7644.jpeg] [image: IMG_7645.jpeg] [image: Image.png] [image: Image (1).png] [image: Image (2).png]"
  },
  {
    "section": "neuro-on-call",
    "sectionName": "Neuro On-Call Quick References",
    "heading": "Migraine Pathway — Quick Reference",
    "id": "migraine-pathway-quick-reference",
    "text": "Migraine Inpatient Management Pathway v.1.0 (2020). Visual quick reference diagram for inpatient acute status migrainosus management."
  },
  {
    "section": "neuro-on-call",
    "sectionName": "Neuro On-Call Quick References",
    "heading": "Pediatric LVO Escalation Pathway",
    "id": "lvo-escalation",
    "text": "Emergency escalation for suspected pediatric large vessel occlusion requiring endovascular intervention. Step 1: Call anesthesia — Age <12 Peds anesthesia, Age >12 adult anesthesia at NCMC. Step 2: Outside hospitals transfer center — Cincinnati Children's (513) 636-9937, University of Kentucky (859) 257-5522, Riley (317) 963-3333, Vanderbilt (615) 936-4444, Nationwide (614) 722-2000."
  },
  {
    "section": "neuromuscular",
    "sectionName": "NeuroMuscular",
    "heading": "Guillain-Barre Syndrome (GBS)",
    "id": "guillain-barre-syndrome-gbs",
    "text": "Autoimmune demyelinating polyradiculopathyVariantsAxonalMiller Fisher (ataxia, ophthalmoplegia, and areflexia)Presents with tingling, weakness, sensory ataxia½ will have antecedent viral illness. GI illness think-- campylobacter½ individuals will have bilateral facial weaknessWeakness progresses rapidly with nadir at 2 weeks for 50% of pts, 3 weeks for 80%, and rest by 4 weeks   DDX: tick paralysis, cord trauma/ischemia, transverse myelitis viral myositis, botulism, poliomyelitis, diphtheria, porphyria, myasthenia, hypophosphatemia and kalemia, intoxications, lyme, acute HIV   Work Up: conside"
  },
  {
    "section": "neuromuscular",
    "sectionName": "NeuroMuscular",
    "heading": "Neonatal Hypotonia Etiology and Exam",
    "id": "neonatal-hypotonia-etiology-and-exam",
    "text": "Causes of Neonatal Hypotonia  Central (most common)HIEIntracranial hemorrhageCerebral malformationChromosomal abnl 21, Prader WilliCongenital infections (TORCHES)Acquired infectionsPeroxisomal disordersDrug effects (benzodiazepines)Spinal CordBirth traumaSyringomyeliaAnterior Horn CellSpinal muscular atrophyNeuromuscular-junctionMyasthenia gravis (transient or congenital)Infantile botulismMuscleMuscular dystrophy (inc congenital myotonic dystrophy)Congenital myopathies (eg. Central core disease)PeripheralHereditary motor and sensory neuropathiesMetabolic myopathiesAcid maltase deficiency (Pomp"
  },
  {
    "section": "neuromuscular",
    "sectionName": "NeuroMuscular",
    "heading": "Spinal Muscular Atrophy (SMA)",
    "id": "spinal-muscular-atrophy-sma",
    "text": "SMA is characterized by degeneration of the anterior horn cells in the spinal cord and motor nuclei in the lower brainstem, which results in progressive muscle weakness and atrophy. The diagnosis of SMA should be suspected for any infant with unexplained weakness or hypotonia. Molecular genetic testing with targeted mutation analysis can confirm the diagnosis of SMA by detection of homozygous deletions of exons 7 of the SMN1 gene.  TypeAge of onsetRequires respiratory support at birthAble to sitAble to standAble to walkLife expectancyPredicted SMN2 copy number0PrenatalYesNoNoNo<6 months11<6 mo"
  },
  {
    "section": "neuromuscular",
    "sectionName": "NeuroMuscular",
    "heading": "Duchenne Muscular Dystrophy (DMD)",
    "id": "duchenne-muscular-dystrophy-dmd",
    "text": "DMD is an X-linked recessive disorder caused by mutations of the dystrophin gene that result in absent or insufficient functional dystrophin protein. Results in progressive muscular weakness, loss of ambulation, respiratory impairment, and cardiomyopathy.     Neuromuscular Management of DMD:    Common comorbid conditions: GI: GERD, constipation, swallowing dysfunction. Need osmotic laxatives, retrograde enemas. Ranitidine or PPIs.Nutrition: obesity usually while on steroids. Underweight due to poor intake. Pulmonary: Complications include respiratory muscle fatigue, mucus plugging, atelectasis"
  },
  {
    "section": "headaches",
    "sectionName": "Headaches",
    "heading": "Emergent Headache Evaluation",
    "id": "emergent-headache-evaluation",
    "text": ""
  },
  {
    "section": "headaches",
    "sectionName": "Headaches",
    "heading": "Thunderclap Headache",
    "id": "thunderclap-headache",
    "text": "Definition: Severe headache reaching maximum intensity within 60 seconds (\"worst headache of my life\"). Must rule out subarachnoid hemorrhage (SAH):\n\nStep 1: Non-contrast CT head — sensitivity ~98% within 6 hours of onset, drops to ~93% at 24h and ~50% by day 5\nStep 2: If CT negative and within 2 weeks of onset → lumbar puncture looking for xanthochromia (send tube 4 for spectrophotometry) and elevated RBCs that do not clear\nStep 3: If LP also negative → consider CTA or MRA to evaluate for unrup"
  },
  {
    "section": "headaches",
    "sectionName": "Headaches",
    "heading": "Headache Red Flags — \"SNOOP\" Mnemonic",
    "id": "headache-red-flags-snoop",
    "text": "S — Systemic symptoms (fever, weight loss, rash) or Secondary risk factors (immunocompromised, malignancy, coagulopathy)\nN — Neurologic signs (papilledema, focal deficits, altered mental status, meningismus)\nO — Onset sudden (thunderclap) or recent onset in child < 5 years\nO — Other associated features: positional (worse lying down → IIH; worse standing → low-pressure), nocturnal or early morning awakening headaches, triggered by Valsalva/cough/exertion\nP — Prior headache history: new headache t"
  },
  {
    "section": "headaches",
    "sectionName": "Headaches",
    "heading": "When to Image a Pediatric Headache",
    "id": "when-to-image-pediatric-headache",
    "text": "Urgent imaging (CT head) indicated if: Thunderclap onset\nFocal neurologic deficits\nPapilledema or loss of venous pulsations on fundoscopy\nAltered mental status or worsening GCS\nSigns of increased ICP: vomiting (especially AM), personality change, head tilt\nPost-traumatic with \"red flag\" features\nVP shunt concern MRI brain (outpatient) consider if: Headache always same side\nHeadache wakes from sleep or present on awakening\nProgressive headache over weeks with new neurologic findings\nAge < 5 with "
  },
  {
    "section": "headaches",
    "sectionName": "Headaches",
    "heading": "IIH Workup Essentials",
    "id": "idiopathic-intracranial-hypertension-workup",
    "text": "Opening pressure thresholds (LP in lateral decubitus): Normal: < 20 cmH₂O (children) or < 25 cmH₂O (adolescents/obese)\nElevated: ≥ 25 cmH₂O (≥ 28 cmH₂O if obese/sedated)\nEnsure child is calm, legs extended — crying can double pressure readings"
  },
  {
    "section": "neuro-ophthalmology",
    "sectionName": "Neuro-Ophthalmology",
    "heading": "Anisocoria Evaluation",
    "id": "anisocoria-evaluation",
    "text": ""
  },
  {
    "section": "neuro-ophthalmology",
    "sectionName": "Neuro-Ophthalmology",
    "heading": "Approach to Unequal Pupils",
    "id": "anisocoria-approach",
    "text": "Key question: Which pupil is abnormal — the large one or the small one? EMERGENCY: Large pupil + ptosis + eye \"down and out\" = CN III palsy until proven otherwise. In a post-operative or head-injured patient, this may indicate uncal herniation requiring emergent neurosurgical evaluation."
  },
  {
    "section": "neuro-ophthalmology",
    "sectionName": "Neuro-Ophthalmology",
    "heading": "Step 1: Examine in Light vs Dark",
    "id": "anisocoria-in-light-vs-dark",
    "text": "Anisocoria greater in light (large pupil doesn't constrict) → problem is with the large pupil\n  \n  CN III palsy (check for ptosis, eye movement limitation)\n  Pharmacologic mydriasis (topical atropine/cyclopentolate — won't constrict to 1% pilocarpine)\n  Traumatic mydriasis (iris sphincter damage)\n  Tonic pupil (Adie) — vermiform movements, slow constriction, constricts to dilute 0.1% pilocarpine (denervation supersensitivity)\n  \n\nAnisocoria greater in dark (small pupil doesn't dilate) → problem "
  },
  {
    "section": "neuro-ophthalmology",
    "sectionName": "Neuro-Ophthalmology",
    "heading": "Horner Syndrome Workup",
    "id": "horner-syndrome-workup",
    "text": "Confirm: Topical 4% cocaine or 0.5% apraclonidine — Horner pupil fails to dilate with cocaine (or reverses with apraclonidine). Localize: Central (1st order): Stroke, demyelination, tumor — MRI brain + cervical spine\nPreganglionic (2nd order): Pancoast tumor, neuroblastoma (pediatric!), carotid dissection — CT/MRI chest + neck\nPostganglionic (3rd order): Carotid dissection, cavernous sinus lesion — MRA head/neck Pediatric Horner: Must rule out neuroblastoma (obtain urine catecholamines — HVA, VM"
  },
  {
    "section": "neuro-ophthalmology",
    "sectionName": "Neuro-Ophthalmology",
    "heading": "CN III Palsy — Surgical vs Medical",
    "id": "cn-iii-palsy-evaluation",
    "text": "\"Surgical\" (pupil-involving): Mydriasis + ptosis + limited adduction/elevation/depression → concern for posterior communicating artery (PComm) aneurysm compression. Urgent CTA/MRA.\n\"Medical\" (pupil-sparing): Ptosis + eye movement limitation but normal pupil → microvascular (diabetes, hypertension). More common in adults; rare in children.\nIn children: Pupil-sparing distinction is less reliable. Any CN III palsy in a child warrants imaging."
  },
  {
    "section": "epilepsy",
    "sectionName": "Epilepsy",
    "heading": "Valproic Acid (VPA) Toxicity",
    "id": "valproic-acid-toxicity",
    "text": ""
  },
  {
    "section": "epilepsy",
    "sectionName": "Epilepsy",
    "heading": "VPA-Induced Hyperammonemic Encephalopathy",
    "id": "vpa-hyperammonemic-encephalopathy",
    "text": "Can occur even with therapeutic VPA levels. Suspect in any patient on VPA with acute confusion, lethargy, vomiting, or worsening seizures."
  },
  {
    "section": "epilepsy",
    "sectionName": "Epilepsy",
    "heading": "Recognition",
    "id": "vpa-toxicity-recognition",
    "text": "Check ammonia level in any encephalopathic patient on valproic acid — even if VPA level is \"therapeutic.\"\n\nAmmonia > 80 µmol/L — clinically significant\nAmmonia > 100 µmol/L — concerning, likely symptomatic\nAmmonia > 200 µmol/L — critical, risk of cerebral edema\n\nAlso check: hepatic function panel (AST, ALT, total/direct bilirubin), VPA level, CBC with platelets, lipase"
  },
  {
    "section": "epilepsy",
    "sectionName": "Epilepsy",
    "heading": "L-Carnitine Treatment Protocol",
    "id": "l-carnitine-protocol",
    "text": "Indication: VPA-induced hyperammonemia with encephalopathy, VPA overdose, or hepatotoxicity.\nIV Levocarnitine (Carnitor):\n\nLoading dose: 100 mg/kg IV (max 6 g) over 30 minutes\nMaintenance: 50 mg/kg IV (max 3 g) every 8 hours\nContinue until ammonia normalizes and mental status improves\nTransition to oral: 50-100 mg/kg/day divided TID (max 3 g/day)\n\nAdditional management:\n\nHold VPA immediately\nConsider lactulose if ammonia critically elevated (> 200 µmol/L)\nMonitor ammonia every 4-6 hours until tr"
  },
  {
    "section": "epilepsy",
    "sectionName": "Epilepsy",
    "heading": "VPA Overdose",
    "id": "vpa-overdose-management",
    "text": "VPA level > 150 mg/L: Significant toxicity likely — L-carnitine, supportive care\nVPA level > 300 mg/L: Severe — consider hemodialysis (VPA is protein-bound at therapeutic levels but saturation occurs at high concentrations, making dialysis more effective)\nVPA level > 850 mg/L: Life-threatening — hemodialysis strongly recommended\nActivated charcoal if within 1-2 hours of ingestion (VPA is well-absorbed)\nNo specific antidote — L-carnitine is the primary treatment adjunct"
  },
  {
    "section": "neuromuscular",
    "sectionName": "Neuromuscular",
    "heading": "GBS — Acute Workup & Management Protocol",
    "id": "gbs-acute-workup",
    "text": ""
  },
  {
    "section": "neuromuscular",
    "sectionName": "Neuromuscular",
    "heading": "Diagnostic Workup",
    "id": "gbs-diagnosis",
    "text": "Lumbar Puncture:\n\nClassic finding: albuminocytologic dissociation (elevated protein, normal WBC < 10/µL)\nCSF protein may be normal in the first week — sensitivity improves after day 7\nIf WBC > 50/µL → reconsider diagnosis (think infectious, HIV, Lyme, CMV)\n\nNCS/EMG:\n\nMay be normal in first 1-2 weeks\nOptimal timing: 2-3 weeks after symptom onset\nEarly findings: prolonged F-waves, prolonged distal latencies, absent H-reflexes\nHelps classify subtype: AIDP (demyelinating, most common) vs AMAN/AMSAN "
  },
  {
    "section": "neuromuscular",
    "sectionName": "Neuromuscular",
    "heading": "Respiratory Monitoring — \"20/30/40 Rule\"",
    "id": "gbs-respiratory-monitoring",
    "text": "Monitor FVC (forced vital capacity) every 4-6 hours in all GBS patients:\n\nFVC < 20 mL/kg → consider ICU transfer / intubation\nNIF (MIP) < -30 cmH₂O → respiratory muscles weakening\nFVC declining > 30% from baseline → rapid progression, prepare for intubation\n\nOther intubation indicators: inability to count to 20 in one breath, paradoxical abdominal breathing, oxygen desaturation, inability to lift head off bed\nDo NOT rely on pulse oximetry alone — desaturation is a LATE finding in neuromuscular r"
  },
  {
    "section": "neuromuscular",
    "sectionName": "Neuromuscular",
    "heading": "Treatment Protocol",
    "id": "gbs-treatment-protocol",
    "text": "IVIG (first-line in pediatrics):\n\nDose: 2 g/kg total, given over 2-5 days (e.g., 0.4 g/kg/day × 5 days)\nCheck IgA level before first dose (IgA deficiency → anaphylaxis risk)\nMonitor for adverse effects: headache, aseptic meningitis, renal dysfunction, thrombosis\n\nPlasmapheresis (PLEX):\n\nAlternative to IVIG — equally effective in severe cases\nTypically 5 exchanges over 1-2 weeks\nPreferred if IVIG contraindicated or patient not improving\nDo NOT give IVIG after PLEX (PLEX removes the IVIG)\n\nSteroid"
  },
  {
    "section": "paroxysms",
    "sectionName": "Paroxysms",
    "heading": "Neonatal Jitteriness vs Seizures",
    "id": "neonatal-jitteriness-vs-seizures",
    "text": "One of the most common consult questions in the nursery/NICU. Key clinical features distinguish jitteriness (benign) from seizures (requires workup). Feature\nJitteriness\nSeizure\n\n\n\n\nMovement type\nTremor (equal amplitude, frequency in both directions)\nClonic (fast phase in one direction, slow return)\n\n\nStimulus-sensitive\nYes — provoked or worsened by stimulation\nNo — occurs spontaneously\n\n\nSuppressible with flexion/restraint\nYes — stops when limb is gently held\nNo — continues despite restraint\n\n\n"
  },
  {
    "section": "paroxysms",
    "sectionName": "Paroxysms",
    "heading": "Common Causes of Neonatal Jitteriness",
    "id": "neonatal-jitteriness-causes",
    "text": "Hypoglycemia (check glucose!)\nHypocalcemia\nNeonatal drug withdrawal (maternal SSRI, opioids)\nHypothermia\nSepsis (can also cause seizures — low threshold to work up)\nIdiopathic / benign neonatal jitteriness (diagnosis of exclusion)"
  },
  {
    "section": "paroxysms",
    "sectionName": "Paroxysms",
    "heading": "If Seizure Suspected — Initial Workup",
    "id": "neonatal-seizure-workup",
    "text": "Stat labs: Glucose, BMP (calcium, magnesium, sodium), blood gas, lactate\nInfection workup: CBC, blood culture, consider LP (CSF studies + HSV PCR)\nEEG: Continuous video EEG monitoring if seizure confirmed or ongoing suspicion\nImaging: Head ultrasound (bedside), MRI brain when stable\nConsider: Urine organic acids, serum amino acids, ammonia if metabolic etiology suspected\nFirst-line treatment: Phenobarbital 20 mg/kg IV loading dose"
  },
  {
    "section": "neurocritical-care",
    "sectionName": "Neurocritical Care",
    "heading": "Step 1: Immediate Measures",
    "id": "icp-step-1",
    "text": "Notify neurosurgery — NSGY typically aids in ICP management\nOptimize sedation and pain control\nHead of bed elevated to 30°, head and neck midline (optimize venous drainage)\nHyperventilate to PaCO₂ 32-35 mmHg (temporary bridge only — do not maintain)\nIf EVD/ICP drain present: unclamp, set at 15 mmHg, notify NSGY\nSee Pupillometry section for noninvasive ICP trending (NPI < 3 = pathological)"
  },
  {
    "section": "neurocritical-care",
    "sectionName": "Neurocritical Care",
    "heading": "Step 2: First-Line — Hypertonic Saline",
    "id": "icp-step-2",
    "text": "3% Hypertonic Saline (HTS) — 0.5 mEq/mL Na⁺\n\nDose: 5 mL/kg IV bolus via peripheral IV or central line\nMay repeat if ICP remains elevated\nHold if serum Na⁺ ≥ 165 mmol/L\nMonitor serum sodium every 4-6 hours"
  },
  {
    "section": "neurocritical-care",
    "sectionName": "Neurocritical Care",
    "heading": "Step 3: Second-Line — Mannitol",
    "id": "icp-step-3",
    "text": "Use if fluid overloaded or not responsive to HTS:\n\nDose: Mannitol 0.5-1 g/kg IV bolus\nHold if serum osmolarity ≥ 340 mOsm/kg\nMay repeat after 15 minutes if ICP remains elevated\nMonitor serum osmolarity, electrolytes, and volume status"
  },
  {
    "section": "neurocritical-care",
    "sectionName": "Neurocritical Care",
    "heading": "Step 4: Refractory ICP",
    "id": "icp-step-4",
    "text": "If ICP remains elevated despite Steps 1-3:\n\nNeuromuscular blockade (eliminates shivering, coughing, ventilator dyssynchrony)\nDeep sedation:\n  \n  Ketamine + midazolam infusion, OR\n  Pentobarbital coma — titrate to burst suppression on cEEG\n  \n\nTherapeutic hypothermia to 32-34°C\nNeurosurgical intervention: decompressive craniectomy, hemicraniectomy"
  }
]